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1.1 Epidemiology
Endometrial cancer is the most common malignancy of the female genital tract in Western
countries, with a stable incidence in the Netherlands over the last decade of approximately 16
per 100,000 women per year. Endometrial cancer is the fourth most common invasive
tumour in Dutch women, and accounts for about 5% of all tumours. In 2000 there were
1457 new cases of endometrial cancer in the Netherlands, with the highest incidence among
women aged 55 -75 years. 316 women died of the disease that year.1 Factors that increase the
exposure of the uterus to unopposed estrogens, either exogenous or endogenous, are associated
with increased risk of endometrial carcinoma.2 Early menarche, late menopause, and no preg-
nancies are classically associated with the development of endometrial cancer. Obesity is
another well-recognized risk factor. Elevated levels of estrogens, due to increased peripheral
conversion of androstenedione, may be the underlying mechanism for this risk. Endometrial
cancer is also known to be associated with several other medical conditions, such as diabetes
and hypertension,3 but it might be that these conditions are simply markers of obesity. Little is
known about genetic influence on the risk of endometrial cancer. An increase in the risk asso-
ciated with family history of endometrial cancer has been observed, especially in women aged
under 50 years,4,5 but less than 1% of all endometrial cancers were found to be attributable to
familial, and hence potentially genetic, factors.5 Women with mutations in either the MLH1
or MSH2 gene, responsible for hereditary non-polyposis colorectal cancer (HNPCC), are also
at increased risk of developing endometrial cancer at younger age. Identification of HNPCC,
or Lynch syndrome, is based on the Amsterdam criteria, stating that at least three relatives
should have histological verified colorectal cancer; one of them should be a first degree relative
to the other two. At least two successive generations should be affected, and in one of the rel-
atives colorectal cancer should be diagnosed before age 50.6 HNPCC is subclassified based on
the presence or absence of extracolonic malignancies: Lynch syndrome II is accompanied by a
high risk for carcinoma of the endometrium.7 Women with the Lynch II syndrome, have a
risk of approximately 20% to develop endometrial cancer before age 50, and this risk increas-
es to 60% by age 70.8
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1.2 Pathology
The most common histological type of endometrial carcinoma is the endometrioid type
(EEC), which accounts for approximately 75% of all cases.9-11 Other histological subtypes, also
referred to as non-endometrioid endometrial carcinomas (NEEC), include serous papillary
carcinoma (5-10%), clear cell carcinoma (1-5%), mucinous carcinoma (1%) and carcinosar-
comas also known as malignant mixed Müllerian tumours (MMMT) (1-5%).11 This latter
type is composed of malignant epithelial and stromal components, and because of this bipha-
sic appearance, the origin of MMMTs has long been debated. Based on molecular genetic
analysis, the current opinion is that these neoplasm's should be considered as metaplastic car-
cinomas.12 Clinical data support the view that MMMTs should be considered high-risk
carcinomas.11,13 Pre-malignant lesions often precede EEC and NEEC. Endometrial intraepithe-
lial carcinoma (EIC) is associated with NEEC, and hyperplasia can precede EEC. EIC is
composed of malignant cells overlying a basement membrane and appears to represent malig-
nant transformation of atrophic surface endometrium. It is found in the adjacent
endometrium of nearly 90% of serous carcinomas.14 Endometrial hyperplasia consists of an
increase in the density or abnormalities in the configuration or distribution of glands.15
Lesions lacking nuclear atypia are designated hyperplasia and those displaying atypia are desig-
nated atypical hyperplasia. Further subclassification of these two forms of hyperplasia is based
on the degree of architectural abnormalities. Proliferations displaying marked architectural
abnormalities are designated complex (atypical) hyperplasia and lesions with lesser degrees of
architectural abnormalities are designated simple (atypical) hyperplasia. Progression of simple
hyperplasia to endometrioid carcinoma is rare (< 2%), whereas progression to carcinoma
occurs in 30% of the patients with complex atypical hyperplasia.16
Endometrial tumours are staged according to the International Federation of Gynecology and
Obstetrics (FIGO) staging system.17 This system closely resembles the TNM classification sys-
tem, a system used for many solid malignancies18 (Table 1). Until the 1980s FIGO used a
clinical staging system.19 In 1988 FIGO designated endometrial cancer a surgically staged
malignancy, partly as a response to publications detailing the inaccuracy of clinical staging and
the importance of extra uterine spread.20 Although mandated through this staging system,
lymphadenectomy of the pelvis and para-aortic areas remains controversial. Many individuals
with endometrial cancer are obese or elderly, with other medical problems, and according to
the FIGO committee on Gynecologic Oncology clinical judgement is required to determine if
additional surgery is warranted. In the Netherlands, a lymphadenectomy is usually not a rou-
tine component of surgical staging in stage I endometrial cancer. Several studies confirmed the
improved prognostic power of the FIGO 1988 surgical staging system, compared with the
former clinical staging system.21,22 Due to the early presenting symptom of vaginal bleeding,
most patients (75-80%) are diagnosed at an early stage, i.e. FIGO stage I.23 The histological
grade is an important prognostic factor in endometrial carcinoma. The most widely used grad-
11
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ing system for endometrial carcinoma is the system recommended by FIGO in 1988. It is pri-
marily based on the extent of nonsquamous solid growth and secondarily on nuclear atypia.
Grade 1 tumours have 5% or less areas of solid growth, grade 2, 6% to 50%, and grade 3
more than 50% solid growth (Figure 1). In case of marked nuclear atypia, a grade 1 or 2 is
raised by one grade. Marked nuclear atypia is defined as cells with markedly enlarged, pleo-
morphic nuclei, displaying irregular coarse chromatin and prominent, eosinophilic
nucleoli.11,24 Most tumours are found to be grade 1 or 2. Only 10-30% of all endometrial car-
cinomas are classified as grade 3, although this percentage is higher in advanced stage
tumours.25 FIGO grading has been shown to have significant prognostic value.26-28 However,
12
Table 1. Pathological FIGO staging system (1988) and TNM classification (2002) for endometrial carcinoma
17,18
TNM* Category FIGO Stage
Tis Carcinoma in situ (preinvasive carcinoma)
T1a Tumour limited to endometrium IA
T1b Invasion to < ½ myometrium IB
T1c Invasion to ≥ ½ myometrium IC
T2a Endocervical glandular involvement only IIA
T2b Cervical stromal invasion IIB
T3a Tumour involves serosa and/or adnexa and/or positive peritoneal cytology IIIA
T3b Vaginal involvement IIIB
N1 Metastases to pelvic and/or para-aortic lymph nodes IIIC
T4 Tumour invades bladder and/or bowel mucosa IVA
M1 Distant metastases IVB
*TNM: T – Primary tumour, N – Regional lymph nodes, M – Distant metastases
Figure 1. Endometrioid endometrial carcinoma. (A) Grade 1. (B) Grade 3.
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several previous studies have questioned the reproducibility of this grading system. Reported
percentages of interobserver agreement vary between 63% and 81% with corresponding κ-values
of 0.49-0.65.29-32 Causes of this lack of reproducibility are the difficulty of distinguishing
between squamous and nonsquamous solid growth, especially in case of immature squamous
metaplasia, the determination of the percentage of nonsquamous solid growth (more or less
than 5%) which is relatively arbitrary, and the subjectivity of the determination of the degree
of nuclear atypia, illustrated by the 35% agreement (κ = 0.22) for nuclear grading reported by
Lax et al.29 Several alternative grading systems for endometrial carcinoma have been proposed
to improve the reproducibility. Lax et al 29 proposed a binary grading system based upon the
proportion of solid growth (50% or less versus more than 50%), the pattern of myometrial
invasion (infiltrating versus pushing border) and the presence of tumour cell necrosis. Taylor
et al 32 divided tumours into low-grade and high-grade based solely on the proportion of solid
growth (more or less than 20%). However, these alternative grading systems need to be tested
on large numbers of endometrial carcinomas, in order to evaluate their improved repro-
ducibility and their prognostic power. The depth of myometrial invasion is, besides the
histological type, FIGO stage, and histological grade, another pathological feature with major
prognostic value in endometrial carcinoma. Deep invasion into the outer part of the myome-
trial width, defined as either the outer 50% or outer 33%, increases the risk of vessel invasion,
since the major vessels of the myometrium are located in the subserosal areas. Deep myometri-
al invasion has been reported to be a strong adverse prognostic factor.27,33-35 However, in daily
practice it is often difficult to determine the depth of infiltration precisely, since it depends on
the way the macroscopic specimen has been processed, which may be subject to sampling
errors. Several investigators evaluated the value of the pattern of myometrial invasion. Two
distinct infiltration patterns have been identified. First, a diffusely infiltrative growth pattern
characterized by irregularly distributed glands, masses, cords, or nests of tumour cells infiltrat-
ing the myometrium haphazardly (infiltrating pattern), and second, an expansive growth
pattern in which the invasive tumour has a lobulated appearance with pushing borders (push-
13
Figure 2. Pattern of myometrial invasion. (A) Pushing border. (B) Infiltrating pattern.
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ing border) 29,36 (Figure 2). The pattern of invasion has been found to be an independent prog-
nostic factor: the infiltrating pattern was indicative of poor clinical outcome.36,37 This might be
due to the fact that in the infiltrative type, the tumour actually grows into the myometrium,
whereas in case of an expansive growth pattern, the tumour pushes the myometrium away,
rather than infiltrating it, without reaching the vessels in the outer part of the myometrium. 
1.3 Prognostic factors
Patients with endometrial carcinoma in general have a good prognosis, since most patients
present with early-stage disease. For stage I endometrial cancer 5-year survival rates are 
80-90%26,34,38,39 and for stage II tumours 60-80%.39,40 A wide range of 5-year survival rates have
been reported for patients with stage III tumours. In most studies rates between 30% and
50% were found,25,41 but survival rates up to 80% have also been reported in selected groups
of patients,42,43 illustrating the diversity of tumours grouped under stage III endometrial carci-
noma. The 5-year survival rate for stage IV disease is approximately 5%.39
Over the last two decades, numerous clinical-pathological factors have been found to have
prognostic power for survival in patients with endometrial carcinoma. Major prognostic fac-
tors include age, FIGO stage, depth of myometrial invasion, histological subtype, lymph
vascular space invasion and histological grade.21,22,26,27,33-35,44-46 Both high oestrogen and high
progesterone receptor levels have been found to be associated with improved survival.47-50
As discussed in §1.4, several molecular abnormalities have been reported to have prognostic
implications, though conclusions are contradictory and the clinical relevance of these observa-
tions has yet to be elucidated.
1.4 Molecular biology
In 1983 Bokhman was the first to describe two different types of endometrial carcinoma.51
Type I tumours are oestrogen-related, often preceded by a hyperplasic condition, and are typi-
cally low-grade endometrioid carcinomas of the endometrium. They usually develop in an
oestrogen rich environment (obesity, pre- and peri-menopausal state), and in general have a
good prognosis. On the other hand, type II tumours are unrelated to oestrogen, mostly devel-
oping in atrophic endometrium, presumably preceded by endometrial intraepithelial
carcinoma, and are more often serous papillary and clear cell carcinomas, i.e. non-endometri-
oid endometrial carcinomas. They affect older women, and usually have a poor clinical
outcome11 (Table 2). The genetic abnormalities involved in the carcinogenesis of endometrial
14
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cancer appear to be different for type I and type II carcinomas. Essentially, every cancer is the
uncontrolled growth that results from a series of mutations in important genes that control
cell cycle, cell death or cellular proliferation. Mutations in three types of genes are believed to
be responsible for the development of most cancers: oncogenes, tumour suppressor genes, and
mismatch repair genes.52 The protein products of oncogenes, such as K-ras and HER-2/neu,
participate in growth pathways in normal cells. A mutation in such a gene causes a change in
the normal cellular protein and can induce unrestrained proliferation. Products from tumour
suppressor genes, such as p53 and PTEN, inhibit cell proliferation. Loss or inactivation of
these genes removes this normal constraint on cellular growth. In addition, p53 responds to
DNA damage either by forcing these cells to go into apoptosis, or by causing cell cycle arrest,
thus promoting DNA repair. Mismatch repair genes, such as MLH1 and MSH2 are responsi-
ble for detecting and correcting lesions in DNA, which have occurred during normal
replication or were caused by environmental agents. A marker for defects in mismatch repair
genes is microsatellite instability (MI). Microsatellites are short, highly polymorphic tracts of
simple repeating units that are widely dispersed throughout the genome and are usually non-
15
Table 2. Predominant features of endometrial carcinoma type I and II 
Characteristic Type I Type II
Estrogen related yes no
Hyperplasia present absent
Histological grade 1 or 2 3
Histological subtype EEC NEEC
Depth of myometrial invasion superficial deep
Stage low high
Prognosis good poor
EEC: endometrioid carcinoma; NEEC: non-endometrioid carcinoma
Table 3. Comparison of major genetic alterations between type I and type II endometrial carcinoma
Genetic alteration Type I Type II
p53 mutations 10-20% 90%
Her-2/neu overexpression 10-15% 20-25%
PTEN inactivation 35-50% 5-10%
K-ras mutations 15-30% 0-5%
Microsatellite instability 20-30% 0-5%
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coding.53 MI refers to alterations in the lengths of these repetitive sequences in tumour DNA
as compared to DNA obtained from normal tissue of the same person. In type II endometrial
carcinomas, p53 mutations seem to be the most important molecular abnormality, reported in
up to 90% of the cases, both in the invasive and in the intraepithelial components, suggesting
this to be an early event in carcinogenesis54,55 (Table 3). HER-2/neu overexpression has been
observed in 10-25% of endometrial carcinomas, more frequently in NEEC than in EEC.56-59
In type I carcinoma (EEC) no specific molecular abnormality has been found to be responsi-
ble for the majority of tumours. This type of endometrial carcinoma seems to encompass a
heterogeneous group of tumours, in which different combinations of several molecular abnor-
malities have been observed. In 10-20% of EEC p53 mutations have been found, mostly in
grade 3 lesions.54,60,61 These mutations have not been found in endometrial hyperplasia, imply-
ing that p53 mutations are late events in the development of EEC, related to dedifferentiation
of endometrioid carcinomas.62 PTEN mutations have been identified in 35-50% of EEC.61,63-65
Since these have also been found in approximately 25% of atypical hyperplasias, this suggests
that PTEN mutations occur early in carcinogenesis. K-ras mutations are found in 15-30% of
EEC and hardly ever in serous papillary or clear cell carcinoma.61,62,65,66 Furthermore, K-ras
mutations have been found in 16% of atypical and simple hyperplasias,62 suggesting that this
mutation is also an early event in a subset of EEC. MI phenotype is present in most endome-
trial carcinomas in patients with the HNPCC syndrome.67 In addition, 20-30% of sporadic
EECs are MI positive.65,67-69 MI has been observed in atypical hyperplasia,69 but not in hyper-
plasia lacking nuclear atypia,70 suggesting it to be a late event in endometrioid carcinogenesis.
The prognostic significance of these molecular changes has been investigated in several stud-
ies. Overexpression of p53 has been reported to be independently related to decreased survival
in endometrial cancer,56,57,71 although it is not yet clear whether this prognostic significance
persists when only EEC are analysed. HER-2/neu overexpression is associated with decreased
survival.56-59 However, in most multivariate analyses, including p53 mutation or DNA ploidy,
its prognostic significance is lost.57,58 Ploidy describes the DNA content of the cell. Normal
cells are diploid, tumour cells often miss DNA or contain extra DNA (aneuploidy).
Aneuploidy is observed in 15-30% of endometrial carcinomas. Since DNA ploidy reflects the
overall degree of genetic damage, it is often found to be a stronger adverse prognostic factor
than other more specific genetic changes.58,72,73 Studies on the prognostic significance of PTEN
show conflicting results. Some authors have reported that loss of PTEN was a poor prognostic
factor,74 whereas others noted that PTEN mutation was associated with improved survival.75,76
Similarly, the prognostic significance of K-ras mutations has not been clarified yet. Some
investigators reported it to be an adverse prognostic factor,77 whereas others reported prognos-
tic implications only in postmenopausal women,78 or no prognostic significance at all.79
Contrary to observations in colon cancer, where MI is reported to be associated with
favourable outcome,80 in a study on endometrial cancer an adverse outcome has been
observed.81 However, most studies do not find any prognostic significance of MI in endome-
16
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trial carcinoma.82-84 Assessment of molecular abnormalities can provide information about the
carcinogenesis of endometrial carcinoma, it can provide prognostic information, and it holds
the promise for improved means of treatment of endometrial cancer. So far, identification of
molecular abnormalities has not yet been implemented in daily clinical practice, because their
prognostic power is not superior to other, traditional factors, such as age, FIGO stage, and
tumour grade. However, further research into this area is worthwhile, because knowledge
about molecular abnormalities may aid to a more refined identification of high-risk and low-
risk subpopulations and may provide the foundation for molecularly directed therapies.
1.5 Treatment
The cornerstone of treatment for most patients with endometrial carcinoma is surgery. In
1878, Freund was the first to perform a successful total abdominal hysterectomy for this dis-
ease.85 By the 1920s the role of irradiation in the management of endometrial carcinoma was
well recognised, either as an adjunct to surgical treatment or as an alternative to operation.
The Stockholm method, an intracavitary technique, reported by Heyman in 1947 86 generated
further interest. With improved surgical outcomes in the 1940s, more patients had surgical
treatment. For the next decades the combination of intracavitary irradiation and surgery was
the treatment of choice.9 By the late 1960s, concerns rose about the complications from this
irradiation technique, and treatment changed to preoperative external beam irradiation.87,88
When it was recognized that many patients who had preoperative irradiation received unnec-
essary radiation, as pathological evaluation postoperatively demonstrated low-risk features,
another approach to treatment was developed by the 1970s: surgery with adjuvant radiothera-
py tailored to prognostic factors.20,89 Three large, prospective, randomised trials have been
conducted to evaluate the effectiveness of postoperative pelvic radiotherapy in stage I endome-
trial cancer. In the study by Aalders et al,35 540 women with clinical (FIGO 1971) stage I
endometrial carcinoma, who had undergone a total abdominal hysterectomy with bilateral
salpingo-oophorectomy (TAH-BSO) and postoperative vaginal radiotherapy (RT) were ran-
domly assigned to additional pelvic RT or observation. This trial included patients with both
high and low risk of recurrence, however, the majority of patients had low-risk features.
Although pelvic RT reduced vaginal and pelvic recurrence rates (2% in the RT versus 7% in
the control group), overall survival was not improved (5-year survival of 89% versus 90%). 
In the multicentre Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)
trial,26 patients with stage I endometrial carcinoma, either grade 1 or 2 with deep (50% or
more) myometrial invasion (stage IC), or grade 2 or 3 with superficial (less than 50%)
myometrial invasion (stage IB), were randomly assigned after TAH-BSO to pelvic RT or
observation. In the RT group the 5-year locoregional recurrence rate was 4% versus 14% in
17
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the observation group (p < 0.001). Again, this difference in locoregional recurrence did not
translate into a survival benefit: 5-year overall survival rates were 85% in the control and 81%
in the RT group (not significant). Risk factors for recurrence were found to be deep myome-
trial invasion (50% or more), histological grade 3 and age 60 years or over. The Gynecological
Oncology Group (GOG) trial included 392 patients with a surgical stage IB-IIB (occult),
node negative endometrial carcinoma, who were randomised to receive no additional treat-
ment (NAT) or pelvic radiotherapy (RT) after TAH-BSO and selective lymphadenectomy.90
The 2-year locoregional recurrence rates were 1.6% and 7.4%, for the RT and the NAT
group, respectively. In this study there was a slight, though not significant, survival benefit: 
4-year overall survival rates were 92% and 86%, for the RT and the NAT group, respectively.
Presently, the standard surgical treatment in the Netherlands for stage I-III endometrial can-
cers is a TAH-BSO. Postoperative radiotherapy is indicated in all stage II or III carcinomas,
and in stage I carcinomas when 2 of 3 risk factors are present (histological grade 3, 50% or
more myometrial invasion, and age 60 years or over).26 The role of a staging lymphadenecto-
my in stage I endometrial carcinoma is controversial. Some authors suggest that it might lead
to a better outcome, and that radiotherapy could be omitted when lymph node metastases are
absent.91-95 However, these small, retrospective studies include highly selected, mostly young
patient groups. Furthermore, other studies did not find a therapeutic benefit,96 and so far it
has not been established that the procedure yields additional prognostic information to the
information obtained at the time of hysterectomy,20,97 while it increases the risk of complica-
tions.97 The results of the ongoing randomised MRC-ASTEC study may clarify in the future
whether or not a staging lymphadenectomy should be a routine component of surgical staging
in stage I endometrial cancer. Chemotherapy and hormonal treatment are used in the treat-
ment of recurrent or metastatic endometrial carcinoma. Response rates with progestins range
from 18% to 34%, with a median duration of several months.98,99 Highest response rates are
achieved in patients with progesterone receptor positive tumours.100,101 In a meta-analysis of 
6 randomised trials, including 3544 patients with endometrial carcinoma, no survival benefit
was found for adjuvant progestational treatment.102 With combined chemotherapy treatment
(doxorubicin or paclitaxel and cisplatin), response rates of 31-67% are reported, but toxicity
rates (mainly haematological) are substantial, and the median duration of these responses is
limited to 7-11 months.103-106 In the adjuvant setting, no benefit of doxorubicin was found.107 
1.6 Aims and outline of this thesis
The prognosis for patients with endometrial carcinoma is known to be dependent on several
clinical and pathological factors. A strong prognostic factor is the histological grade. However,
the reproducibility of the most commonly used three-tiered FIGO grading system has been
18
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questioned in several studies. With the use of prognostic factors, subgroups of patients with
distinct outcome perspectives, requiring different therapies, can be identified. Incorporation
of molecular biologic information could further differentiate between low-risk and high-risk
subgroups of patients and could also provide the foundation for further scientific research on
molecularly directed therapies. The purpose of this thesis was to investigate the significance of
prognostic factors in endometrial carcinoma, especially the value of the FIGO grading system.
Furthermore, the incidence and significance of molecular abnormalities and their potential
role as prognostic factors for clinical practice was evaluated.
The patient data and histology specimens of two patient cohorts were analysed. First, a cohort
of 253 patients with endometrial carcinoma FIGO stages I to III, who were treated in the
Leiden University Medical Center (LUMC) between 1984 and 1993 was retrospectively
analysed. In 233 cases (89%), tumour samples could be obtained for immunohistochemical
analyses. Secondly, data and histology specimens from the multicentre Post Operative
Radiation Therapy in Endometrial Carcinoma (PORTEC) trial were analysed. Between 1990
and 1997, this trial included 714 evaluable patients with a FIGO stage I endometrial carcinoma.
Histology specimens for review were obtained in 80% of the cases.
In chapter 2 the long-term outcome and prognostic factors for the 253 patients of the LUMC
study is analysed and described. Median follow-up of this retrospective analysis was over 
10 years. The prognostic value of FIGO stage, histological grade, age, myometrial invasion
(depth and pattern), and histological subtype was analysed, focussing on the value of histolog-
ical grade. 
In 2000, the outcome of the randomised PORTEC trial was published. The objectives of this
Dutch multicentre trial were to compare locoregional control and overall survival of patients
with a stage I endometrial carcinoma, treated with postoperative pelvic radiotherapy or sur-
gery alone. In chapter 3 the long-term outcome of the 714 patients included in this trial, and
the results with central pathology review are presented.
Chapter 4 describes the results of a histological grading study of 800 endometrial carcinomas.
The slides of 231 patients (91%) from the LUMC study, and of 569 patients (80%) from the
PORTEC trial could be obtained for this study. These 800 cases were reviewed and graded
independently by two pathologists. The prognostic significance and the interobserver variabil-
ity of two grading systems were compared: the traditionally used three-tiered FIGO grading
system and a two-tiered grading system, based on the amount of solid growth, the pattern of
myometrial invasion and the presence of tumour cell necrosis.
In chapter 5 the expression of E-cadherin, α- and β-catenin in 225 endometrial carcinomas is
evaluated. The correlation between E-cadherin and the catenins, and their correlation with
several histological and clinical parameters was analysed, as well as their prognostic value.
In chapter 6 it is investigated whether an abnormality in the Wnt/β-catenin signalling path-
way, leading to nuclear β-catenin expression, is a molecular feature of type I endometrial
19
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carcinoma. β-catenin expression was investigated in 233 endometrial carcinomas. The correla-
tions with several immunohistochemical, histological and clinical parameters, such as the
proliferation rate (Ki-67), oestrogen and progesterone receptor expression, and survival were
analysed. In chapter 7 a summary is given, and the results and their implications for clinical
practice are discussed.
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Chapter 2
Long-term outcome in endometrial carcinoma favours 
a two- instead of a three-tiered
grading system
Astrid N. Scholten, Carien L. Creutzberg,
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Abstract
Purpose: Endometrial carcinoma is the most common malignancy of the female genital
tract. Recognized prognostic factors include FIGO stage, histological grade, depth of myome-
trial invasion, and age. Although determination of these factors may seem clear and
reproducible, the histological grade has recently been the subject of debate. A retrospective
analysis of long-term outcome and prognostic factors in endometrial carcinoma was conduct-
ed, focusing on the prognostic value of tumour grade.
Materials and Methods: The study included 253 patients with endometrial carcinoma
stages I to III, who were treated between 1984 and 1993. The histological slides were reviewed
and the prognostic value of stage, age, myometrial invasion (depth and pattern), tumour
grade, and histological subtype was analysed. The end point was cancer-specific death; the
median follow-up time was 11.7 years.
Results: The actuarial 5-year and 10-year cancer-specific survival rates (CSS) were 85% and
82%, respectively. The 5-year vaginal or pelvic recurrence and distant relapse rates were 7% and
15%. In multivariate analysis, stage, pattern of myometrial invasion, tumour grade, and age
were independent prognostic factors. At pathology review, a shift from grade 2 to grade 1 was
seen in 112 of the original 144 grade 2 lesions (78%). There was no difference in CSS between
grade 1 and grade 2 (94% vs. 90% for original grade and 92% vs. 94% for grade after review),
whereas grade 3 was found to be a significant adverse prognostic factor ( p < 0.001).
Conclusions: The independent prognostic factors for patients with endometrial cancer
were stage, pattern of myometrial invasion, tumour grade, and age. Systematic grading led to
a considerable shift from grade 2 to grade 1. However, there was no difference in prognostic
significance between grade 1 and 2, whereas grade 3 was a major adverse prognostic factor. A
two-tiered grading system, instead of the currently used three-tiered system seems preferable,
because it has a better correlation with clinical outcome and is expected to have less interob-
server variability. 
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Introduction
Endometrial cancer is the most common malignancy of the female genital tract in Western
countries, with an incidence in The Netherlands of approximately 16 per 100,000 women per
year.1 Over the last two decades, numerous clinical-pathological factors have been found to
predict survival in patients with endometrial carcinoma. Recognized prognostic factors
include stage, tumour grade, myometrial invasion, and age.2-5 Although the determination of
these factors may seem clear and reproducible, the tumour grade has recently become a sub-
ject of debate.6,7 Currently, the most widely used grading system for endometrial carcinoma is
the system recommended by the International Federation of Gynecology and Obstetrics
(FIGO) in 1988. It is primarily based on the extent of nonsquamous solid growth and sec-
ondarily on nuclear atypia.8 Recently, the reproducibility of this three-tiered grading system
was shown to be poor, with a high interobserver variability (κ = 0.63).6 This was especially due
to the difficulty in consistent nuclear grading (κ = 0.22).7 A two-tiered system was proposed,
which divides tumours into poorly differentiated and well-differentiated tumours. This system
showed greater inter- and intraobserver reproducibility and had a better correlation with clin-
ical outcome.7 The depth of myometrial invasion has been proven to be of prognostic
significance.2-5 However, the determination of the depth of invasion is not always easy and
depends on the way the macroscopic specimen has been processed. 
Our analysis was done to determine the long-term results of treatment for endometrial cancer
and to analyse risk factors for relapse, including the depth as well as the pattern of myometri-
al invasion and focusing on the prognostic value of tumour grade. This retrospective study
included all patients who were treated in our institution with curative intent for endometrial
carcinoma during a 10-year period. With the long follow-up time (median 11.7 years), we
were able to illuminate many aspects of the clinical course of this tumour.
Materials and Methods
Patients and treatment
From January 1984 to December 1993, 253 patients with endometrial carcinoma (FIGO
stages I-III) were referred to the Department of Radiotherapy at the Leiden University
Medical Center (LUMC). During that period, all patients with an endometrial carcinoma had
an indication for post-operative radiotherapy, except those with a stage I, well-differentiated
adenocarcinoma (grade 1) of the endometrium, with less than 50% myometrial invasion.
These were not included in this study.
Surgery had been performed in the LUMC or in a regional hospital, and consisted of a total
abdominal hysterectomy and bilateral salpingo-oophorectomy in most cases (91%). Fourteen
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patients (5%) underwent a radical hysterectomy, and the remaining 4% underwent a vaginal
hysterectomy. Additionally, peritoneal fluid was sent for cytological evaluation in 21% of
cases. A lymphadenectomy was performed in 4% of cases; pelvic and periaortic nodes were
sampled in 5% of all cases. For most patients (84%), postoperative radiotherapy consisted of
whole pelvic external irradiation followed by vaginal brachytherapy. Thirty-eight patients
(15%) received external irradiation only, and three patients (1%) were treated by brachythera-
py only. Pelvic irradiation was delivered using a four-field box technique, to a total dose of
40-50 Gy, in 2 Gy daily fractions. The target volume included the proximal half of the vagina,
the previous site of the uterus and adnexa, as well as the internal and external iliac nodes. The
dose was specified at the isocenter of the fields. Dose homogeneity requirements were accord-
ing to the criteria of the International Commission on Radiation Units and Measurements.
Brachytherapy (low-dose-rate, LDR) was delivered using either colpostats or a vaginal cylin-
der, to a dose of 15-20 Gy. The dose was specified at 5 mm from the vaginal surface. Further
details about the radiotherapy are shown in Table 1.
Four patients received adjuvant systemic therapy, because of advanced disease (FIGO stage
III). Therapy consisted of progestional agents for two patients, and two patients received adju-
vant chemotherapy (three courses of cyclophosphamide, hexamethylmelamine, adriamycin,
and cisplatinum, CHAP).
Pathology review
The histopathological slides of 246 patients (97%) were reviewed by one pathologist (V.S.),
especially with respect to myometrial invasion and grade, according to the FIGO 1988 grad-
ing criteria.8 Patient and tumour characteristics are shown in Table 2. Malignant mixed
Müllerian tumours (carcinosarcomas) and papillary serous carcinomas were not graded, but
were considered as grade 3 in the multivariate analysis. In case of malignant cells in the
Table 1. Postoperative radiotherapy
Radiotherapy modality Number of patients (%) Median dose (Gy) SD Range
External beam and brachytherapy 212 (84) 40 1.3 40 - 50
15* 0.7 15 - 20
External RT alone 38 (15) 50 6.9 40 - 64
Brachytherapy alone 3 (1) 50* 11.5 33 - 55
SD: standard deviation * Low dose rate (60-80 cGy/hr)
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adnexa, tumours were classified as stage III
endometrial carcinoma, when histology and
grade were identical to the primary lesion 
(n = 22). All other cases (n = 4) were consid-
ered to be synchronous ovarian carcinomas.
Other stage III tumours were classified as
such because of positive peritoneal cytology
(n = 8), pelvic lymph node involvement 
(n = 3), or vaginal involvement (n = 1).
Data collection and statistics
Follow-up data were collected from the
patient charts, the cancer registry, and the
patients’ general practitioners. All patients
have been followed for a minimum of six
years (median follow-up duration 11.7 years,
range 6.3 – 16.8 years) or until death.
Survival, local control, and late side effect
rates were calculated using the Kaplan-Meier
method, and differences between survival
curves were assessed with the log-rank test.
In instances of ordered variables, the trend
test was used. Multivariate analysis of prog-
nostic factors was performed using the Cox
proportional hazards model. All factors with
a p-value < 0.10 in univariate analysis were
included in the multivariate analysis. 
The original tumour grade was left out of
the main multivariate analysis, and was
analysed in a separate multivariate analysis,
in which it replaced the tumour grade after
review. The endpoint for the survival analy-
sis was cancer-specific death, calculated from
initial treatment with censoring at date of
last contact or death due to other causes than
endometrial carcinoma.
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Table 2. Patient and tumour characteristics
Characteristic Number of patients (%)
Age (years)
< 60 77 (30)
≥ 60 176 (70)
mean 65.1





endometrioid adenocarcinoma 241 (95)
papillary serous carcinoma 8 (3)










< 50% 91 (37)
≥ 50% 155 (63)
* myometrial invasion and grade assigned at pathology review
† malignant mixed Müllerian tumours and papillary serous 
lesions were all considered grade 3
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Results
Outcome
Overall (OS), disease-free (DFS), and cancer-specific (CSS) actuarial survival rates at five years
were 77%, 75%, and 85%, and 10-year survival rates were 64%, 63%, and 82%, respectively
(Figure 1). At the time of this analysis (January 2001) 105 patients had died. Two patients
(2%) died of locally recurrent endometrial cancer, 45 (43%) died of metastatic disease, and 
44 (42%) of intercurrent disease. One patient (1%) died of treatment complications, and in 
13 cases (12%) the cause of death was unknown.
Relapses occurred in 48 patients (20%). In most cases (n = 40), distant metastases were the
first site of relapse. Vaginal, pelvic, and periaortic lymph node recurrences were seen as first
site of relapse in five, two, and one cases, respectively. Vaginal or pelvic lymph node recur-
rences were diagnosed synchronously with a distant relapse in seven and nine cases,
respectively. Distant metastases developed after the diagnosis of a local or regional recurrence
in three and one cases, respectively. In this analysis we refer to vaginal or pelvic recurrences as
locoregional recurrences. The 5-year rates of locoregional recurrences and distant metastases
were 7% and 15%, respectively. Various clinical and pathological factors were analysed for
their value in predicting clinical outcome, as defined by CSS. The results of univariate and
multivariate analyses are shown in Table 3. Because of their small number (n = 12), malignant
mixed Müllerian tumours and papillary serous carcinomas were grouped together in this
analysis. There was no significant difference in CSS between patients with these two histolog-
ical subtypes (data not shown). It can be seen in Table 3 that stage, tumour grade, pattern of
myometrial invasion, and histological subtype all had prognostic significance for CSS in uni-
variate analysis. A subanalysis of stage IIIA tumours revealed no significant difference in
survival between the patients with a stage IIIA tumour because of adnexal involvement and
those with IIIA due to positive peritoneal cytology, with 5-year CSS rates of 58% and 63%,
respectively (p = 0.63). In multivariate analysis, histological subtype did not reach prognostic
significance. Stage, tumour grade, pattern of myometrial invasion, and age appeared to be
independent prognostic factors. We have calculated survival after the occurrence of a relapse
and analysed several factors for their prognostic significance. Two-year overall survival rates
after locoregional and distant relapse were 57% and 12%, mean survival time was 2.4 years
and 5 months, respectively (p = 0.01, Figure 2). We analysed several pretreatment variables,
namely, age, stage, tumour grade, myometrial invasion and histological subtype, and in addi-
tion the interval between initial diagnosis and the occurrence of a relapse (less than two years
vs. two years or more). None of these factors was found to predict survival after a locoregional
recurrence. In case of distant metastases, an interval of more than two years between the initial
diagnosis and the relapse resulted in a significantly better 2-year survival rate compared with
an interval of less than two years, 22% vs. 4%, p = 0.04 (median survival five and four
months, respectively).
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Complications
Complications were recorded and graded using the EORTC/RTOG system.9 Due to the retro-
spective nature of the study, mild complications (grade 1) could not be assessed. Late side
effects of radiotherapy, defined as those occurring more than one month after completion of
irradiation, were seen in 17 patients. Twelve patients had radiation proctitis. Other complica-
tions included cystitis (n = 2), small bowel obstruction (n = 2), and vaginal ulcer (n = 1).
Table 3. Univariate and multivariate analysis of risk factors related to cancer-specific survival
5 yr. UV MV
Variable n (%) CSS % p-value HR (95% CI) p-value
Stage
I 185 (73) 91 1
II 34 (13.5) 79 3.4 (1.6-7.3)
III 34 (13.5) 58 < 0.001 3.7 (1.8-7.6) < 0.001
Tumour grade: after review
1 164 (67) 92 1
2 19 (8) 94 0.4 (0.1-3.3)
3 63 (25) 63 < 0.001 3.6 (1.8-7.1) < 0.001
Tumour grade: original
1 53 (21) 94 1
2 144 (57) 90 1.8 (0.7-5.1)
3 56 (22) 63 < 0.001 4.6 (1.7-12.7) 0.004
Myometrial invasion: depth
< 50% 91 (37) 89 1
≥ 50% 155 (63) 82 0.07 1.0 (0.5-2.0) 0.99
Myometrial invasion: pattern
pushing border 91 (39) 90 1
infiltrating pattern 141 (61) 80 0.01 2.2 (1.1-4.4) 0.03
Histology
endometrioid adenocarcinoma 241 (95) 87 1
other 12 (5) 57 < 0.001 1.2 (0.8-1.6) 0.36
Age (years)
< 60 77 (30) 89 1
≥ 60 176 (69) 83 0.07 2.4 (1.1-5.1) 0.02
UV: univariate analysis; MV: multivariate analysis; HR: hazard ratio
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Using the actuarial method, the complication rate at five years was 6.6%. Severe late compli-
cations (≥ grade 3) were seen in four patients: one patient developed a radiation proctitis,
because of which she required several blood transfusions; one patient had persistent haema-
turia (for which coagulation was required); and one patient developed a vaginal ulcer. One
patient with a small bowel obstruction died due to heart failure after the required operation.
The 5-year actuarial severe late complication rate was 1.7%.
Other malignancies
Second (and in three cases even third) primary tumours were diagnosed in 28 patients (11%).
Seven patients had a second gynaecological tumour, simultaneously with their endometrial
carcinoma, but of distinct pathology. In 21 patients a second (or third) primary tumour was
diagnosed, which consisted mostly of breast (n = 6) and colorectal cancers (n = 7). In addi-
tion, 11 patients had been treated for other cancers before the diagnosis of their endometrial
cancers (five breast cancers, one cancer of the colon, five other sites).
Pathology review
The histopathological slides of 246 patients (97%) were reviewed. The diagnosis of endome-
trial carcinoma was confirmed in all cases. Seven cases (3%) were assigned a different depth of
myometrial invasion, 118 (47%) were assigned a different tumour grade, as compared to the
original grade at the time of diagnosis, and in nine cases (4%) both grade and myometrial
invasion were scored differently by the reviewing pathologist. One-hundred twenty-two of all
144 cases originally assigned grade 2 (78%) shifted to grade 1 at review. Ten cases (6%) shift-
ed from grade 2 to grade 3. The reviewer assigned a different grade to original grades 1 and 3
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Figure 1. Cancer-specific survival. Figure 2. Survival after relapse according to first 
site of relapse (p = 0.01).
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in five cases. These different assignments
consisted of a shift from grade 1 to grade 2
(one case), a shift from grade 1 to grade 3
(one case), a shift from grade 3 to grade 2
(one cases), and a shift from grade 3 to grade
1 (one case). It can be seen in Table 3 that
the considerable shift from grade 2 to grade
1 did not influence the CSS rates. Patients
with grade 1 and grade 2 tumours had equal
survival rates, whereas patients with a grade
3 tumour had a significantly worse outcome.
Figure 3 shows the CSS by revised tumour
grade and illustrates the fact that the diagno-
sis of grade 3 is associated with an
unfavourable prognosis, whereas grades 
1 and 2 both predict a favourable outcome 
(p < 0.001). At pathology review, we identified distinct infiltration patterns. Whereas some
tumours infiltrated in a diffuse way, with nests of tumour cells infiltrating the myometrium
haphazardly, others showed an expansive growth pattern, with pushing borders and a continu-
ous line between tumour and unaffected myometrium. A pushing border was found in
91 cases, an infiltrating pattern in 141 cases. In 14 cases there was no invasion or the pattern
of invasion could not be assessed. The pattern of myometrial invasion was found to be an
independent prognostic variable, with a survival benefit for patients with a tumour with a
pushing border as opposed to patients with infiltrating tumours. There was no significant cor-
relation between the pattern of myometrial invasion and the tumour grade.
Discussion
Survival rates for patients with endometrial carcinoma are highly dependent on the extent of
disease. We found 5-year cancer-specific survival (CSS) rates of 91% and 79% for patients
with stage I and stage II tumours, respectively. These numbers are in accordance with survival
rates reported in previous studies.2,4,10,11 In this study, survival for patients with advanced pri-
mary disease (FIGO stage III) dropped significantly to a 5-year CSS rate of 58%. A wide
variation in 5-year survival rates is reported for patients with stage III tumours. Most studies
report rates between 30% and 50%,12-14 but survival rates up to 80% have also been reported
in certain groups of patients,15,16 illustrating the diversity of tumours grouped under stage III
endometrial carcinoma. Although we found a difference in 5-year CSS in favour of patients
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Figure 3. Cancer-specific survival according to
tumour grade (p < 0.001).
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with a stage IIIA tumour based on positive peritoneal cytology, as compared to those with a
stage IIIA tumour based on adnexal involvement (63% vs. 58%), this difference did not reach
statistical significance. This might be due to the small numbers of stage IIIA patients in this
study (22 and 8, respectively). Because most patients present with early-stage disease, the
prognosis for patients with endometrial carcinoma is generally good. Nonetheless, in some
patients treatment fails. The chances of survival for these patients are severely impaired. For
patients with distant metastases, reported median duration of survival is 7-8 months.13,17
Survival after a vaginal or pelvic relapse is also impaired, with 2-year survival rates of 20-
65%.18 We found that survival for patients with a locoregional recurrence was significantly
better than for those with a distant relapse, with 2-year survival rates of 57% and 12%,
respectively. However, mean survival of 2.4 years after a locoregional recurrence remains poor.
We have analysed several variables for their prognostic value for clinical outcome after the
occurrence of a relapse. The interval between initial treatment and relapse was found to be a
significant prognostic factor. Survival for patients with a distant relapse diagnosed less than
two years after initial treatment was significantly worse than for those with longer intervals.
However, the difference in mean survival, four months vs. five months, respectively, seems to
be of little practical relevance. Prognosis after a locoregional relapse did not depend on the
interval between initial treatment and relapse, contrary to data published by Morgan et al 19
None of the analysed pretreatment variables - age, stage, tumour grade, myometrial invasion
and histological subtype - proved to be of any prognostic significance.
Because salvage probabilities after a relapse are modest, and survival is impaired, the preven-
tion of such a relapse is an important therapeutic goal. Locoregional control rates have
improved significantly since the introduction of postoperative radiotherapy. This was proven
by two large, prospective, randomized trials, evaluating the effectiveness of postoperative
pelvic radiotherapy in patients with stage I endometrial carcinoma.2,4 Locoregional relapse
rates were 2% after postoperative vaginal brachytherapy and additional pelvic radiotherapy,
compared with 7% after brachytherapy only,4 and 4% vs. 14% after postoperative pelvic
radiotherapy as compared to no adjuvant irradiation.2 Distant relapse and survival rates were
not affected by adjuvant radiotherapy: 7% and 8% distant relapses, and 85% and 81% 5-year
overall survival rates, for patients with surgery only and patients with postoperative radiother-
apy, respectively.2
We found a comparable locoregional relapse rate, but a higher 5-year distant relapse rate (7%
and 15%, respectively), reflecting the use of radiotherapy in all patients and the inclusion of
more advanced stages in this study, unlike the studies mentioned above.
The considerable difference in survival after a distant relapse as compared to survival after a
locoregional relapse suggests a difference in tumour biology. Determination of molecular
markers, e.g., proliferation or apoptotic markers or hormone receptors, could help to predict
the occurrence of a relapse and might even enable us to differentiate between patients at risk
of a locoregional vs. a distant relapse. Accurate identification of patients at increased risk of
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either of the two relapse patterns would be an important step towards a more individualized
treatment, where different subsets of patients with different risk estimations receive different
adjuvant treatment regimens.
Contrary to previously published data, the depth of myometrial invasion was not found to be
a significant prognostic factor in our study, whereas the pattern of invasion had clear prognos-
tic value. At pathology review, we identified two distinct patterns of invasion, an infiltrating
pattern and a pattern with a pushing border.7 We found a significant survival benefit, both in
univariate and in multivariate analysis, for patients with tumours invading with a pushing
border as opposed to patients with infiltrating tumours. There was no significant correlation
between the pattern of myometrial invasion and the tumour grade. Other independent prog-
nostic factors for a worse clinical outcome were older age, advanced stage of disease, and poor
histological grade. Although all these factors have been found to have significant prognostic
value in earlier studies,2-5 the tumour grade requires further elaboration.
We have reviewed and graded all tumours using the standard three-tiered system as introduced
by FIGO in 1988.8 The considerable shift of the tumour grade at revision is probably due to
the relative subjectivity of the determination of nuclear atypia, the presence of which causes a
grade to be raised by one grade, most frequently from grade 1 to grade 2. Furthermore, at
time of review, slides were consistently scored according to the FIGO 1988 grading criteria,
whereas these criteria had not yet been implemented in all hospitals at the time of the
patients’ treatment (between 1984 and 1993). The considerable shift from grade 2 to grade 1
is in accordance with data from the Postoperative Radiation Therapy in Endometrial
Carcinoma (PORTEC) trial reported by Creutzberg et al.2 In their study, the initial pathology
showed 21%, 68%, and 11% grade 1, 2, and 3 tumours, respectively, as opposed to 60%,
32%, and 8% grade 1, 2, and 3 tumours at review.
Recently, the practical clinical utility and reproducibility of the moderate grade of differentia-
tion (grade 2) have been the subject of debate.6,7 In our study, patients with a grade 1 or grade
2 tumour had equal CSS rates, whereas those with a grade 3 tumour had a significantly worse
outcome (p < 0.001). This was the case both for the grade as assigned by the original patholo-
gist and for the grade assigned at review, despite the considerable shift from grade 2 to grade
1, which explains why the revised grade had no better prognostic value than the original. 
The same phenomena were observed in the PORTEC trial.2 In that trial, the revised grade had
no better prognostic power than the original grade and there was hardly any difference in
prognostic significance between grade 1 and grade 2, whereas grade 3 was a major adverse
prognostic factor. It can be concluded that the intermediate grade does not have sufficient dis-
criminating power to be of clinical value. A grading system with two grades, discriminating
between high-risk and low-risk cases, as proposed by Lax et al 7 seems to be preferable.
Identifying low-risk patients would prevent overtreatment. At our pathology review, 34 cases
were diagnosed to have grade 1, stage I tumours with less than 50% myometrial invasion,
implying that these cases lost their indication for radiotherapy, or in other words never had
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such an indication.
Late side effects found in this study appear to be comparable to those previously report-
ed,3,11,20,21 although a proper comparison is difficult because most reported incidences are
absolute numbers, rather than actuarial rates. We found 5-year overall and severe complication
rates of 6.6% and 1.7%, respectively. These low rates might be due to the retrospective nature
of this study, as only severe complications were rigorously assessed. Creutzberg et al 2 found an
overall late complication rate of 25% in their prospective study. Although most of these side
effects were mild (grade 1), the impact on daily life for most patients cannot be ignored. 
In conclusion, new prognostic factors are needed to identify those patients at increased risk of
relapse, leading to a worse clinical outcome. We have confirmed the strong prognostic value of
several easily definable adverse prognostic factors for CSS: advanced stage, older age, and poor
histological grade. Since distinguishing a grade 2 tumour from a grade 1 has no additional
prognostic value, the two-tiered grading system as proposed by Lax et al 7 seems preferable to
the traditional three-tiered FIGO grading system. We are currently analysing and comparing
the reproducibility and the prognostic value of these two grading systems in a large group of
cases from the current study and from the prospective PORTEC trial.2
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Abstract
Background: In 2000, the results of the multicentre Post Operative Radiation Therapy in
Endometrial Carcinoma (PORTEC) trial were published. This trial included 714 stage I
endometrial carcinoma patients randomly assigned to postoperative pelvic radiotherapy (RT)
or no further treatment, excluding those with stage IC, grade 3 or stage IB, grade 1 lesions.
Radiotherapy significantly decreased the risk of locoregional recurrence (4% vs. 14%), with-
out affecting overall survival. In this report the long-term outcome and results with central
pathology review are presented.
Methods: The slides of 569 patients (80%) could be obtained for pathology review. Median
follow-up for patients alive was 97 months. Analysis was done according to the intention-to-
treat principle. The primary study endpoints were locoregional recurrence and death.
Results: Ten-year locoregional relapse rates were 5% (RT) and 14% controls,  p < 0.0001,
and 10-year overall survival was 66% and 73%, respectively (p = 0.09). Endometrial cancer
related death rates were 11% (RT) and 9% (control, p = 0.47). Pathology review showed a
substantial shift from grade 2 to grade 1, but no significant difference for grade 3. When cases
diagnosed at review as grade 1 with superficial myometrial invasion were excluded from the
analysis, the results remained essentially the same, with 10-year locoregional recurrence rates
of 5% (RT) and 17% (controls, p < 0.0001).
Conclusions: In view of the significant locoregional control benefit, radiotherapy remains
indicated in stage I endometrial carcinoma patients with high-risk features for locoregional
relapse.
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Introduction
In 2000, the results of the multicentre Post Operative Radiation Therapy in Endometrial
Carcinoma (PORTEC) trial were published.1 Patients were eligible for this trial if they had a
stage I endometrial carcinoma, either grade 1 or 2 with deep (50% or more) myometrial inva-
sion (stage IC), or grade 2 or 3 with superficial (less than 50%) myometrial invasion (stage
IB). Eligibility was based on the grade assigned by the regional pathologist. After total abdom-
inal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) patients were randomised
to receive pelvic radiotherapy or no further treatment. Of a total of 715 randomised patients,
714 could be evaluated; 354 were assigned to radiotherapy (RT) and 360 to no further treat-
ment. The study groups were well balanced for characteristics such as age, concurrent
morbidity, histological grade, and myometrial invasion.1 The risk of locoregional recurrence
decreased significantly with RT (5-year locoregional recurrence rates of 14% and 4%, respec-
tively), without affecting overall survival (5-year overall survival rates of 85% and 81% for the
RT group and the control group). However, the analysis had been done with the grade
assigned by the regional pathologist and a substantial shift from grade 2 to grade 1 was found
at pathology review.1,2 Due to this shift, some tumours were diagnosed as grade 1 tumours
with superficial myometrial invasion (stage IB), and would not have met the inclusion criteria
for the study. The present analysis was done to determine whether exclusion of these
favourable cases would alter the trial outcome, and to present long-term results.
Materials and Methods
Pathology review
The slides of 569 patients (80%) could be obtained for pathology review. Slides were graded
independently by two pathologists (V.S. and H.B.), according to the FIGO 1988 grading cri-
teria,3 blinded to patient outcome. For cases that were graded differently a consensus grade
was obtained during a joint evaluation session.2 Cases without pathology review were included
in the analyses as a separate category ND (not done). 
Statistics
Overall survival, and locoregional (vaginal or pelvic, or both) recurrence rates were calculated
using the Kaplan-Meier method, and differences between survival curves were assessed with
the log-rank test. Median follow-up for patients alive was 97 months. Analysis was done
according to the intention-to-treat principle. The primary study endpoints were locoregional
recurrence and death. Multivariate analysis of prognostic factors was performed using the Cox
proportional hazards model. All p-values are based on two-sided tests.
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Results
Locoregional recurrences were diagnosed in 13 patients assigned to radiotherapy and in 47
patients assigned to observation. The 10-year actuarial locoregional relapse rates were 5% in
the RT group and 14% in the control group (p < 0.001, Figure 1A). There was no significant
survival difference between the treatment arms, with 10-year actuarial overall survival rates of
66% (RT) and 73% (controls) (p = 0.09, Figure 1B). Most patients died of intercurrent dis-
eases. Endometrial cancer related death rates were similar: 11% in the RT group and 9% in
the control group at 10 years (p = 0.47). Five-year survival after any relapse was 13% in the
RT group and 48% in the control group (p < 0.001). Most locoregional relapses were isolated
vaginal recurrences (73%). In the control group, salvage therapy for a vaginal recurrence is
effective with an actuarial 5-year survival rate of 70% compared with 38% in the RT group.
Ten-year locoregional recurrence rates were 7%, 11% and 18% for revised grades 1, 2 and 3 (p
= 0.005, Figure 2A), and 10-year rates of death due to endometrial cancer were 5%, 12% and
31%, respectively (p < 0.0001). In multivariate analyses, postoperative radiotherapy was found
to be an independent prognostic factor for locoregional recurrence (Hazard ratio (HR) 3.8; p <
0.0001), but not for death due to endometrial cancer (Table 1). For patients aged below 60,
60-70 years and 70 years or over, 10-year locoregional recurrence rates were 4%, 11% and 13%
(p = 0.007, Figure 2B), and 10-year rates of death due to endometrial cancer were 5%, 9% and
14%, (p < 0.0001). Ten-year locoregional recurrence rates according to the depth of myometri-
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Figure 1. (A) Probability of locoregional (vaginal 
or pelvic) relapse for patients assigned to
radiotherapy or no further treatment 
(p < 0.001). 
(B) Probability of survival for patients assigned to
radiotherapy or no further treatment (p = 0.09).
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al invasion (less than 50% vs. 50% or more) were 6% and 12%, respectively (p = 0.07, Figure
2C), and 10-year rates of death due to endometrial cancer were 8% and 11% for tumours with
superficial (less than 50%) and deep (50% or more) myometrial invasion, respectively (p =
0.47). Patients with at least 2 of 3 risk factors (age 60 years and over, histological grade 3 and
50% or more myometrial invasion) were found to have an increased risk of locoregional
relapse, and thus to have the highest absolute benefit of pelvic RT. The 10-year locoregional
relapse rates in this "high-risk" category were 4.6% in the RT group and 23.1% in the control
group. At pathology review a substantial shift from grade 2 to grade 1 was observed.2
Originally, 21%, 68% and 11% of tumours were assigned grade 1, 2 and 3, respectively, while
after pathology review, this changed to 69%, 16% and 15%. Due to this shift, 134 tumours
were diagnosed as grade 1 tumours with superficial myometrial invasion (stage IB), and would
not have met the inclusion criteria for the study. After exclusion of these 134 cases from the
analyses, outcome remained essentially the same, with 10-year recurrence rates of 5% for the
RT group and 17% for the control group (p < 0.0001), and 10-year overall survival rates of
65% and 70%, respectively (p = 0.23). 
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Table 1. Cox-regression analyses
Locoregional relapse Death due to EC
n (%) Events HR (95% CI) p-value Events HR (95% CI) p-value
All patients 714 (100) 60 65
No radiotherapy 360 (50) 47 3.8 (2.0-7.0) < 0.0001 30 0.7 (0.4-1.2) 0.17
Age ≥ 60 514 (72) 53 3.4 (1.5-7.5) 0.0005 56 2.6 (1.3-5.3) 0.003
Invasion ≥ 50% 420 (59) 42 1.9 (1.1-3.3) 0.03 41 1.7 (1.0-2.9) 0.048
Grade 0.005 < 0.0001
Grade 2* 88 (12) 9 2.0 (0.9-4.2) 0.08 9 2.1 (0.9-4.6) 0.07
Grade 3* 86 (12) 14 3.5 (1.8-6.8) 0.0003 25 9.3 (5.0-17.4) < 0.0001
Grade ND* 145 (20) 13 2.0 (1.0-3.9) 0.049 11 1.9 (0.9-4.0) 0.09
Exclusion of grade 1 with < 50% invasion
All patients 580 (100) 55 62
No radiotherapy 286 (46) 43 3.8 (2.0-7.2) < 0.0001 29 0.7 (0.4-1.2) 0.25
Age ≥ 60 435 (75) 49 3.5 (1.5-8.2) 0.0009 54 2.7 (1.3-5.7) 0.003
Invasion ≥ 50% 420 (72) 42 1.9 (0.9-3.8) 0.07 41 1.5 (0.8-2.8) 0.18
Grade 0.02 < 0.0001
Grade 2* 88 (15) 9 2.0 (0.9-4.5) 0.10 9 1.9 (0.8-4.3) 0.14
Grade 3* 86 (15) 14 3.5 (1.6-7.5) 0.002 25 8.1 (4.0-16.7) < 0.0001
Grade ND* 145 (25) 13 2.0 (0.9-4.2) 0.07 11 1.7 (0.8-3.8) 0.18
EC: Endometrial Carcinoma; HR: Hazard Ratio; * versus grade 1
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Discussion
Postoperative radiotherapy for FIGO stage I endometrial carcinoma has been a subject of con-
troversy due to the low relapse rate and the lack of randomized trials. In 2000, the results of
the PORTEC study were published, showing pelvic RT to provide a highly significant
improvement of local control, but without a survival advantage. Furthermore, RT was found
to be a very effective salvage treatment for vaginal relapse in patients not previously irradiated.
Pelvic RT was associated with a small (3%) risk of grade 3 complications, but with a substan-
tial (22%) risk of mild, mainly gastrointestinal side effects, of which 50% were transient.4
It was concluded that the use of pelvic RT should be limited to those patients at sufficiently
high risk of locoregional relapse (15% or over) to warrant the risk of treatment associated
morbidity in order to maximize initial local control and relapse-free survival. Patients with 
2 of the 3 major risk factors grade 3, age 60 or over, and outer 50% myometrial invasion, were
found to be at increased risk of locoregional relapse and to have the highest absolute benefit of
pelvic RT (23% versus 4.6% at 10 years). 
In the PORTEC trial, low risk patients were identified for whom the indication for postoper-
ative radiotherapy could be omitted. These results have influenced the guidelines for
treatment of endometrial cancer worldwide. However, the main criticism has been the fact
that the results were based on the grade assigned by the regional pathologist, while a signifi-
cant shift from grade 2 to grade 1 had been observed at pathology review. Therefore, the
current analysis was conducted, with a median follow-up of 97 months, based on the grade
48
Figure 2. Probability of locoregional (vaginal or
pelvic) relapse (A) According to revised
grade (p = 0.005).
(B) According to age group (p = 0.007). 
boek04.qxp  23-3-2005  7:55  Pagina 48
diagnosed at pathology review. The actuarial
10-year locoregional relapse rates were 5% in
the RT group and 14% in the control group
(p < 0.0001). There was no significant sur-
vival difference between the treatment arms,
with 10-year overall survival rates of 66%
(RT) and 73% (controls, p = 0.09). Recently,
the results of the randomized Gynecologic
Oncology Group (GOG-99) trial have been
published,5 which included 392 evaluable
patients with FIGO stage IB, IC or II
(occult disease) of any histological grade.
After TAH-BSO and lymphadenectomy the
patients were randomly assigned to pelvic
RT or no additional treatment (NAT). A
high-intermediate risk group (HIR) was
identified based on age and three other risk
factors for recurrence: (1) histological grade 2 or 3; (2) presence of lymph vascular invasion;
and (3) outer-third myometrial invasion. The HIR subgroup was defined as: (1) 70 years and
1 risk factors; (2) 50-70 years and 2 risk factors; or (3) < 50 years and 3 risk factors. RT pro-
vided a hazard reduction for any relapse of 54%, which resulted in a 58% hazard reduction
and a 14% absolute benefit for the HIR group (4-year relapse 13% after RT, versus 27% for
NAT), results similar to the PORTEC trial. For comparison we applied the GOG high-risk
definition to the PORTEC data, which yielded similar results: 10-year locoregional relapse for
the high-risk group 7.5% after RT versus 21.7% in the control group (details not shown).
Apart from the presence of lymph vascular invasion, which in the PORTEC data was found to
be a risk factor for distant recurrence rather than for locoregional recurrence,6 the prognostic
factors identified in both trials were similar. The high-risk criteria, however, were chosen dif-
ferently. Primary endpoint of the PORTEC trial was locoregional relapse, whereas definition
of the high-risk group in the GOG study was based on the risk of developing any relapse.
Both in the PORTEC trial1 and in a previous study7 we found that outcome for patients with
grade 1 or 2 tumours was similar, whereas those with a grade 3 tumour had a significantly
worse outcome, indicating that, from a clinical point of view, the discrimination between
grade 1 and grade 2 is not very useful. Moreover, it was shown that the reproducibility of
identifying grade 1 and 2 tumours was poor.2 The PORTEC results show that the risk of
locoregional recurrence is almost similar for patients aged 60-70 and for those 70 years and
over, in contrast to patients younger than 60 years who have a significantly more favourable
outcome (Figure 2B), and that the strongest cut-off for age would be 60 years. Main message
from both the PORTEC and the GOG analyses is that these criteria accurately identify those
49
(C) According to depth of myometrial invasion 
(p = 0.07).
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patients with stage I endometrial carcinoma at high risk for relapse, which would benefit from
radiotherapy. 
In conclusion, previous analyses from the PORTEC trial using the grade assigned by the orig-
inal pathologist showed postoperative pelvic radiotherapy for stage I endometrial carcinoma to
significantly decrease the risk of locoregional recurrence, but without a survival advantage.
The current analysis with long-term follow-up and central pathology review confirms these
results, which also persisted when grade 1 carcinomas with superficial myometrial invasion
were excluded. In view of the significant locoregional control benefit, radiotherapy remains
indicated in stage I endometrial carcinoma patients with high-risk features for locoregional
relapse. 
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Abstract
Purpose: The most widely used histological grading system for endometrial carcinoma is
the three-tiered International Federation of Gynecology and Obstetrics (FIGO) system.
Although FIGO grading has significant prognostic value, the reproducibility of grade 2 is lim-
ited. Recently, a binary grading system was proposed based on the amount of solid growth,
the pattern of myometrial invasion, and the presence of tumour cell necrosis. The authors
analysed and compared the prognostic significance and the interobserver variability of both
grading systems and of the three criteria for the binary grading system.
Materials and methods: Eight hundred patients with stage I-III endometrioid endometrial
carcinoma were reviewed and graded independently by two pathologists according to the
three-tiered FIGO grading system and the novel binary grading system.
Results: The interobserver agreement for both systems was moderate, with 70% and 73%
agreement rates for the FIGO (κ = 0.41) and binary (κ = 0.39) grading systems, respectively.
When converting the FIGO grading system into an artificial, two-tiered grading system
(grade 3 vs. grades 1-2), the agreement was much better (agreement rate, 85%; κ = 0.58). Of
the three criteria for the binary grading system, amount of solid growth (50% or less vs. more
than 50%) had the greatest reproducibility (agreement rate, 80%; κ = 0.50). Both the two-
tiered FIGO grading system and the binary grading system were significant predictors of local
recurrence, distant recurrence, and cancer-specific survival (hazard ratios [HRs]: 1.7, 2.5, and
2.6, respectively, for FIGO and 2.1, 4.1, and 3.8, respectively, for the binary grading system).
The amount of solid growth also was a strong prognostic factor for these three endpoints
(HRs: 2.4, 3.9, and 3.8, respectively).
Conclusions: Both the binary grading system and the FIGO grading system had strong
prognostic significance. Their reproducibility, however, was limited. A simple architectural
binary grading system that divided tumours into low-grade lesions and high-grade lesions
based on the proportion of solid growth (less than 50% vs. 50% or more) had superior prog-
nostic power and greater reproducibility.
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Introduction
The most widely used grading system for endometrial carcinoma is the three-tiered
International Federation of Gynecology and Obstetrics (FIGO) system. This histological grad-
ing system is based on both architectural (proportion of solid growth) and cytonuclear
criteria.1 It has been shown that FIGO grading has significant prognostic value.2-5 However, in
a previous retrospective study of 253 patients with stage I-III endometrial carcinoma,5
we found that patients with grade 1 or 2 tumours had equal cancer-specific survival rates
(92% and 94% 5-year survival, respectively), whereas patients with grade 3 tumours had a sig-
nificantly worse outcome (63% 5-year survival), indicating that, from a clinical point of view,
the discrimination between grade 1 and grade 2 is not very useful. Moreover, it was shown
that the reproducibility of identifying grade 1 and 2 tumours was poor. Initial pathologic
examination identified 21%, 57%, and 22% grade 1, 2, and 3 tumours, respectively, com-
pared with 67%, 8%, and 25% grade 1, 2, and 3 tumours, respectively, at review. A similar
shift from grade 2 to grade 1 was reported in a large, Dutch, multicenter, prospective, ran-
domised study, known as the Post Operative Radiation Therapy in Endometrial Carcinoma
(PORTEC) trial,3 which included 714 patients with stage I endometrial carcinoma. Lax et al 6
have proposed a new binary grading system that discriminates between high-grade and low-
grade tumours based on the proportion of solid growth (50% or less vs. more than 50%), the
pattern of myometrial invasion (infiltrating vs. pushing border), and the presence of tumour
cell necrosis. Those authors found that their binary system had superior interobserver agree-
ment compared with the traditional, three-tiered FIGO grading system. Furthermore, it
proved to have prognostic significance for survival.
We conducted a review of 800 patients with endometrioid adenocarcinoma of the endometri-
um. All slides were reviewed independently by two pathologists and were graded according to
both the three-tiered FIGO grading system and the novel binary grading system proposed by
Lax et al.6 The objectives of the current study were to analyse and compare the prognostic sig-
nificance, as well as the interobserver variability, of both grading systems and, separately, to
analyse and compare the three criteria for the binary grading system.
Materials and methods
Patients
A total of 800 patients with endometrioid endometrial carcinoma from two different studies
were analysed. The histopathological slides of hysterectomy specimens from 231 patients
(91%) from a retrospective study5 of 253 patients with stage I-III endometrial carcinoma who
underwent surgery and received radiotherapy at the Leiden University Medical Center were
55
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obtained. Follow-up data were collected
from the patient charts, from the cancer reg-
istry, and from the patients' general
practitioners. All patients were followed for a
minimum of six years or until death (median
follow-up, 9.8 years). In addition,
histopathological slides of hysterectomy
specimens from 569 of 714 patients (80%)
who were included in the PORTEC trial3
were obtained. That trial included patients
with FIGO stage I endometrial carcinoma
who were randomised to receive pelvic
radiotherapy or no further treatment after
undergoing a total abdominal hysterectomy
and bilateral salpingo-oophorectomy. Of the
569 patients who were included in the cur-
rent study, 279 patients received
postoperative radiotherapy, and 290 patients
received no further treatment. The median
follow-up was 6.5 years. Patient, tumour,
and treatment characteristics are shown in
Table 1. The histological diagnosis of
endometrial carcinoma was confirmed in all
patients.
Grading systems
The 800 slides were graded independently by two pathologists (V.S. and H.B., who were
blinded to the patient outcomes) using two different systems: the three-tiered FIGO grading
system and the recently proposed binary grading system. The FIGO grading system is based
primarily on the proportion of nonsquamous solid growth. Grade 1 tumours have 5% or less
areas of solid growth, grade 2 tumours have 6-50% areas of solid growth, and grade 3 tumours
have more than 50% areas of solid growth. In patients with marked notable nuclear atypia, a
grade 1 or 2 is raised by one grade. Notable nuclear atypia is defined as the presence of cells
with markedly enlarged, pleomorphic nuclei that display irregular, coarse chromatin and
prominent, eosinophilic nucleoli.7 The FIGO grading system was analysed not only as a three-
tiered grading system but also when converted into an artificial, two-tiered grading system
(grade 3 vs. grades 1-2). The binary grading system classifies a tumour as "high-grade" if at
least two of three architectural features are present: 1) more than 50% solid growth, without
distinction between squamous and nonsquamous differentiation; 2) a diffusely infiltrative
56
Table 1. Patient, tumour, and treatment characteristics
Characteristic Number of patients (%)
Age (years)
< 60 203 (25)











< 50% 309 (39)
≥ 50% 491 (61)
Total 800
FIGO: International Federation of Gynecology and Obstetrics
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growth pattern characterized by irregularly distributed glands, masses, cords, or nests of
tumour cells infiltrating the myometrium haphazardly, in contrast to an expansive growth pat-
tern in which the invasive tumour has a lobulated appearance with pushing borders; and 3)
tumour cell necrosis, defined as areas of necrotic tumour immediately adjacent to viable
tumour, whereas necrotic debris within masses of squamous epithelium is not qualified as
tumour cell necrosis.6 The pattern of myometrial invasion was judged as infiltrative if glands
or tumour cells haphazardly infiltrated the myometrium, by which there was no longer a more
or less smooth border between tumour and myometrium, even when this happened in only a
small part of the tumour. In addition to the analyses of the FIGO and binary grading systems,
the three criteria for the binary grading system also were analysed separately for their prognos-
tic significance and interobserver variability. For tumours that were graded differently by the
two pathologists, a consensus grade was obtained during a joint evaluation session. These con-
sensus grades were used for the recurrence and survival analyses.
Statistics
Analysis of the interobserver variability was based on the percentage of agreement and was
assessed by the statistic. The κ-values, as measurements of agreement, are interpreted as fol-
lows: 0.00-0.39, poor; 0.40-0.75, fair to good; and 0.76-1.00, excellent.8 In the outcome
analyses, only stage I tumours (92%) were included, because of the relatively small number of
advanced-stage tumours (8%). Recurrence and survival rates were calculated using the
Kaplan-Meier method, and differences between curves were assessed with the log-rank test. In
instances of ordered variables, the trend test was used. Multivariate analysis of prognostic fac-
tors was performed using the Cox proportional hazards model. Several multivariate analyses
were conducted. The baseline model included age, radiotherapy use, and depth of myometrial
invasion. Subsequently, the following factors were added separately: the FIGO grade, the
binary grade, the proportion of solid growth, the pattern of myometrial invasion, and the





The results of grading by the two pathologists according to the three-tiered FIGO grading sys-
tem are shown in Table 2. The interobserver agreement for this grading system was fair 
(κ = 0.41; 70% agreement). When analysing the FIGO grading system as a two-tiered grading
system (i.e., grade 3 vs. grades 1-2), interobserver agreement was much better (κ = 0.58; 85%
57
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Table 2. Grading results from the FIGO grading system
Pathologist 1: Number of patients (%)
Results grade 1 grade 2 grade 3 Total
Pathologist 2
grade 1 430 (54) 18 (2) 4 (1) 452 (57)
grade 2 102 (13) 7 (1) 12 (1) 121 (15)
grade 3 77 (10) 27 (3) 123 (15) 227 (28)
Total 609 (76) 52 (7) 139 (17) 800 (100)
κ 0.41
Consensus 522 (65) 135 (17) 143 (18) 800 (100)
FIGO: International Federation of Gynecology and Obstetrics
Table 3. Grading results from the binary grading system
Pathologist 1: Number of patients (%)
Results low-grade high-grade Total
Pathologist 2
low-grade 462 (58) 15 (2) 477 (60)
high-grade 200 (25) 123 (15) 323 (40)
Total 662 (83) 138 (17) 800 (100)
κ 0.39
Consensus 570 (71) 230 (29) 800 (100)
Table 4. Results using individual grading criteria for the binary grading system
Pathologist 1: Number of patients (%)
Solid growth Myometrial invasion Necrosis
Results ≤ 50% (-) > 50% (+) pushing (-) infiltrating (+) absent (-) present (+)
Pathologist 2
(-) 499 (63) 17 (2) 195 (25) 29 (3) 488 (61) 16 (2)
(+) 146 (18) 138 (17) 204 (26) 363 (46) 194 (24) 102 (13)
κ 0.50 0.41 0.36
Consensus 623 (78) 177 (22) 368 (46) 432 (54) 554 (69) 246 (31)
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agreement). After the combined grading session, 522 tumours (65%) were considered consen-
sus FIGO grade 1 lesions, 135 tumours (17%) were considered FIGO grade 2 lesions, and
143 tumours (18%) were considered FIGO grade 3 lesions.
Binary grading system
The grading results according to the two-tiered grading system are shown in Table 3. 
The interobserver agreement for this grading system was almost similar to that of the FIGO
grading system (κ = 0.39; 73% agreement). After the combined grading session, 570 tumours
(71%) were considered binary low-grade lesions, and 230 tumours (29%) were considered
binary high-grade lesions. The interobserver variability of the three separate criteria also was
analysed. It can be seen in Table 4 that judgment of the proportion of solid growth had the
best reproducibility (κ = 0.50; 80% agreement). Determining the pattern of myometrial inva-
sion (Figure 1A-D) and the presence of tumour cell necrosis (Figure 2A-B) appeared to be
more difficult (κ = 0.41 and 0.36, respectively; 71% and 74% agreement, respectively).
When analysing correlations between the three criteria, we found a strong correlation between
the proportion of solid growth and the presence of necrosis. Sixty-seven percent of tumours
with more than 50% solid growth had necrotic areas, compared with 20% of tumours with
50% or less solid growth (p < 0.001). The pattern of myometrial invasion was correlated 
significantly with the depth of invasion. Seventy-three percent of patients who had tumours
with an infiltrating pattern showed deep myometrial invasion (50% or more), compared with
47% of patients who had tumours with pushing borders (p < 0.001). Both the pattern and the
depth of myometrial invasion were correlated with patient age. Older patients (age 60 years or
over) had tumours that more often showed deep myometrial invasion (67% vs. 46% for
patients aged below 60 years; p < 0.001) and an infiltrating pattern of invasion (56% vs. 47%;
p = 0.03). When comparing the FIGO grading system with the binary grading system, we
found a significant correlation between both systems. Among the binary low-grade tumours,
95% were FIGO grade 1 or 2 lesions (82% and 13%, respectively), whereas only 24% and
27% of the binary high-grade tumours were FIGO grade 1 or 2 lesions, respectively 
(p < 0.001). 
Outcome
Locoregional recurrences (vaginal, pelvic, or both) were diagnosed in 55 of 740 patients with
stage I tumours (7%). The 5-year and 10-year locoregional recurrence rates were 7% and 9%,
respectively. Distant metastases were found in 63 patients (9%), in most instances involving
multiple sites. Distant recurrence rates at five years and ten years were 8% and 9%, respective-
ly. During follow-up, 205 patients (28%) died. Sixty-six deaths (32%) were related to
endometrial carcinoma; 130 patients (64%) died of intercurrent diseases; and, in nine patients
(4%), the cause of death was unknown. The 5-year and 10-year cancer-specific survival rates
were 93% and 90%, respectively. The prognostic value of postoperative radiotherapy, age
59
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Table 5. Univariate analyses of prognostic factors for locoregional recurrence, distant recurrence, and cancer-specific survival
LR* DR* CSS*
Variable n (%) 5-year % p-value 5-year % p-value 5-year % p-value
Age
< 60 179 (24) 3 5 97
≥ 60 561 (76) 8 0.005 8 0.07 92 0.009
Radiotherapy
yes 446 (60) 3 8 93
no 294 (40) 13 < 0.001 7 0.82 93 0.95
Myometrial invasion
< 50% 292 (39) 6 7 94
≥ 50% 448 (61) 8 0.10 8 0.37 92 0.15
FIGO grade
1 491 (66) 5 3 97
2 126 (17) 8 8 94
3 123 (17) 14 < 0.001 25 < 0.001 76 < 0.001
Binary grade
low 537 (73) 5 3 96
high 203 (27) 11 0.01 18 < 0.001 84 < 0.001
Solid growth
≤ 50% 585 (79) 6 4 96
> 50% 155 (21) 11 0.02 19 < 0.001 83 < 0.001
Infiltrating pattern
pushing 346 (47) 7 6 94
infiltrating 394 (53) 7 0.94 9 0.16 93 0.62
Necrosis
absent 526 (71) 6 5 95
present 214 (29) 8 0.37 14 < 0.001 87 < 0.001
LR: locoregional recurrence; DR: distant recurrence; CSS: cancer-specific survival; FIGO: International Federation of Gynecology and Obstetrics
* Total number of events: LR, 55; DR, 63; CSS, 66
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(below 60 years vs. 60 years and over), and depth of myometrial invasion (less than 50% vs.
50% or more) was analysed for locoregional recurrence, distant recurrence, and cancer-specif-
ic survival. In univariate (Table 5) and multivariate (Table 6) analyses, no postoperative
radiotherapy (Hazard ratio [HR]: 4.5) and age (HR: 3.6) were identified as prognostic param-
eters for locoregional recurrence. Age (HR: 2.0) was a significant prognostic factor for distant
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Table 6. Multivariate analyses of prognostic factors for locoregional resurrence, distant recurrence, and cancer-specific survival
LR DR CSS
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Baseline model
Age ≥ 60 3.6 (1.4-9.0) 0.007 2.0 (1.0-4.0) 0.045 2.7 (1.3-5.7) 0.009
No RT 4.5 (2.4-8.1) < 0.001 0.9 (0.5-1.5) 0.65 0.9 (0.6-1.6) 0.87
Myometrial invasion ≥ 50% 1.8 (0.9-3.3) 0.05 1.6 (0.9-2.7) 0.10 1.8 (1.0-3.0) 0.04
Separate addition of the following factors
FIGO grade
2 vs. 1 2.0 (0.9-4.0) 0.06 2.2 (1.1-4.4) 0.03 1.4 (0.7-3.0) 0.37
3 vs. 1 3.6 (1.9-6.7) < 0.001 7.7 (4.4-13.6) < 0.001 7.4 (4.3-12.6) < 0.001
3 vs. 1-2 1.7 (1.3-2.3) < 0.001 2.5 (1.9-3.2) < 0.001 2.6 (2.0-3.3) < 0.001
Binary high-grade 2.1 (1.2-3.7) 0.006 4.1 (2.5-6.8) < 0.001 3.8 (2.3-6.1) < 0.001
Solid growth > 50% 2.4 (1.3-4.3) 0.004 3.9 (2.4-6.5) < 0.001 3.8 (2.3-6.2) < 0.001
Infiltrating pattern 0.8 (0.5-1.4) 0.51 1.4 (0.8-2.3) 0.23 1.0 (0.6-1.7) 0.99
Necrosis 1.3 (0.8-2.3) 0.33 2.9 (1.7-4.7) < 0.001 2.6 (1.6-4.3) < 0.001
LR: locoregional recurrence; DR: distant recurrence; CSS: cancer-specific survival; HR: hazard ratio; 95% 
CI: 95% confidence interval; RT: postoperative radiotherapy; FIGO: International Federation of Gynecology and Obstetrics
recurrence. Age (HR: 2.7) and the depth of myometrial invasion (HR: 1.8) were significant
prognostic factors for cancer-specific survival.
FIGO grading system
The consensus FIGO grade was identified as a significant predictor of locoregional recurrence,
distant recurrence, and overall survival. The 5-year locoregional recurrence rates were 5%, 8%,
and 14% for grades 1, 2, and 3, respectively (p < 0.001). The 5-year distant recurrence rates
were 3%, 8%, and 25% for grades 1, 2, and 3, respectively (p < 0.001); and the 5-year cancer-
specific survival rates were 97%, 94%, and 76%, respectively (p < 0.001, Figure 3A). In
multivariate analysis, FIGO grade proved to be of independent prognostic significance for
locoregional recurrence (HR: 2.0 for grade 2, 3.6 for grade 3; p = 0.06 and p < 0.001, respec-
tively, Table 6). FIGO grade also proved to be of independent prognostic significance for distant
recurrence (HR: 2.2 for grade 2, 7.7 for grade 3; p = 0.03 and p < 0.001, respectively), and can-
cer-specific survival (HR: 7.4 for grade 3; p < 0.001). When converting the FIGO grading
system into a two-tiered grading system (grade 3 vs. combined grades 1 and 2), FIGO grading
still proved to be of independent prognostic significance for locoregional recurrence, distant
recurrence, and cancer-specific survival (HR: 1.7, 2.5 and 2.6, respectively; all p ≤ 0.001).
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Binary grading system
The consensus grade according to the binary grading system had prognostic significance for
locoregional recurrence, distant recurrence, and cancer-specific survival. The 5-year locore-
gional recurrence rates were 5% and 11% for low-grade tumours and high-grade tumours,
respectively (p < 0.001); the 5-year distant recurrence rates were 3% and 18%, respectively 
(p < 0.001); and the cancer-specific survival rates at five years were 96% and 84%, respective-
ly (p < 0.001, Figure 3B). In multivariate analysis, the binary grade had independent
prognostic significance for locoregional and distant recurrence and for cancer-specific survival
(HR: 2.1, 4.1 and 3.8, respectively; p ≤ 0.006, Table 6). Of the three separate criteria for the
binary grading system, both more than 50% solid growth and the presence of necrosis proved
to be significant independent adverse prognostic factors for distant recurrence and cancer-spe-
cific survival. The proportion of solid growth also was identified as a strong, independent
prognostic factor for locoregional recurrence. The HRs for each endpoint were comparable to
those of the binary grading system and were better than the HRs for the artificially created,
two-tiered FIGO grading system. For tumours with 50% or less and for those with more than
50% solid growth, the 5-year locoregional recurrence rates were 6% and 11%, respectively 
(p = 0.02), and the cancer-specific survival rates at five years were 96% and 83%, respectively
(p < 0.001, Figure 3C). Combining the proportion of solid growth and the presence of necro-
sis did not improve prognostic power (data not shown). The pattern of myometrial invasion
did not have prognostic power. 
Figure 3. Cancer-specific survival. (A) According to
FIGO grade (p < 0.001).
(B) According to binary grade (p < 0.001). 
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Discussion
Determining histological tumour grade is an
essential part of pathological diagnosis,
because the histological grade has prognostic
and therapeutic implications. In general, a
grading system has to be practical, repro-
ducible, and clinically relevant, with clear
prognostic power. For endometrial carcino-
ma, the most widely used grading system is
the three-tiered FIGO grading system.
Several previous studies have questioned the
reproducibility of this grading system.
Reported percentages of interobserver agree-
ment vary between 63% and 81%, with
corresponding κ-values of 0.49-0.65.6,9-11
This is comparable to the reproducibility that we observed for FIGO grading (70% agree-
ment; κ = 0.41). In a previous study, we also showed that the reproducibility associated with
identification of grade 2 tumours was poor.5 At pathology review, a shift from grade 2 to grade
1 was seen in 78% of the original grade 2 tumours. Moreover, the outcome of patients with
grade 1 and grade 2 tumours was practically identical (92% and 94% 5-year survival, respec-
tively), which brings into question the clinical value of grade 2.
There are several features of the FIGO grading system that may be responsible for this lack of
reproducibility. First, distinguishing between squamous and nonsquamous solid growth can
be difficult, especially in patients with immature squamous metaplasia. Second, determining
whether the percentage of nonsquamous solid growth is more or less than 5%, which distin-
guishes architecturally whether a tumour is a grade 2 or grade 1 lesion, is somewhat arbitrary.
Finally, the determination of the degree of nuclear atypia is highly subjective, as illustrated by
the 35% agreement (κ = 0.22) for nuclear grading reported by Lax et al.6 Several alternative
grading systems for endometrial carcinoma have been suggested to improve the reproducibili-
ty without loosing prognostic power. Lax et al 6 proposed a binary grading system based on
the proportion of solid growth, the pattern of myometrial invasion, and the presence of
tumour cell necrosis. Taylor et al 11 divided tumours into low-grade and high-grade lesions
based solely on the proportion of solid growth.
We conducted the current study to compare the clinical value of the FIGO grading system,
the binary grading system proposed by Lax et al,6 and the three separate factors for that binary
grading system (solid growth, pattern of myometrial invasion, and necrosis) by analysing their
reproducibility and their prognostic value in 800 patients with endometrioid endometrial car-
cinoma. The interobserver agreement of the binary grading system was almost similar to that
63
(C) According to proportion of solid growth 
(p < 0.001).
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of the three-tiered FIGO grading system (73% agreement; κ = 0.39), and was comparable to
the 79% agreement reported by Lax et al 6 When we analysed the FIGO grading system as a
two-tiered grading system (grade 3 vs. grades 1-2), interobserver agreement proved to be
much better (85% agreement, κ = 0.58). With regard to the interobserver variability among
the three separate criteria for the binary grading system, judgment of the proportion of solid
growth showed 80% agreement (κ = 0.50). Determining the pattern of myometrial invasion
was more difficult (71% agreement; κ = 0.41). This difficulty probably was caused by dis-
agreement of the two pathologists on a considerable number of tumours with an essentially
expansive growth pattern but with some masses or cords of tumour cells infiltrating the
myometrium superficially. More detailed definitions of the pattern of myometrial invasion
may improve the uniformity in differentiating between both patterns of invasion. It was found
that the reproducibility of the presence of tumour cell necrosis was poor (74% agreement; κ =
0.36). Lax et al 6 stated that necrotic debris within masses of squamous epithelium did not
qualify as tumour cell necrosis. Judging a necrotic mass as either debris or necrosis often was a
matter of debate between the two pathologists. Furthermore, tumour cell necrosis was defined
as areas of necrotic tumour immediately adjacent to viable tumour, and that criterion also
proved to be somewhat subjective.
In the current study, it was found that the prognostic value of both the FIGO and the binary
grading systems was good. In multivariate analyses, both FIGO grade 3 and the binary high-
grade were identified as independent adverse prognostic factors for locoregional recurrence
(HR: 3.6 and 2.1, respectively), distant recurrence (HR: 7.7 and 4.1), and cancer-specific sur-
vival (HR: 7.4 and 3.8). Although the HR for patients with FIGO grade 3 tumours versus
patients with grade 1 tumours was greater than the HR for patients with binary high-grade
tumours versus patients with low-grade tumours, the binary grading system was superior to
the FIGO grading system when the FIGO grading system was converted into a two-tiered
grading system. HRs for FIGO grade 3 versus grades 1-2 for locoregional and distant recur-
rences and for cancer-specific survival were 1.7, 2.5, and 2.6, respectively. Lax et al 6 stated
that FIGO grade 1 and grade 2 tumours are not equivalent to low-grade tumours in the bina-
ry system; the low-grade tumour group was smaller than the FIGO grade 1 and grade 2
tumour groups combined (97 patients and 119 patients, respectively). The current results
confirm this conclusion, because we found less low-grade tumours than FIGO grade 1 or
grade 2 tumours (570 patients and 657 patients, respectively). Still, we found a strong correla-
tion between both grading systems (p < 0.001), explaining why the prognostic value of both
grading systems was so similar.
Taylor et al 11 compared the three-tiered FIGO grading system with another two-grade system.
For 82 patients with stage I or II endometrioid adenocarcinoma, the percentage of nonsqua-
mous solid areas (in increments of 10%) was scored. The 20% nonsquamous solid growth
pattern was chosen to delineate high-grade and low-grade tumours. It was shown that the
reproducibility of this grading system was very good (99% agreement; κ = 0.97), and the
64
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Figure 1. Patterns of myometrial invasion. (A) Pushing border. (B) Case of disagreement (consensus, pushing
border). (C) Case of disagreement (consensus, infiltrating pattern). (D) Infiltrating pattern. 
Figure 2. Necrosis. (A) Necrosis. (B) Case of disagreement (consensus, necrosis).
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authors reported that their system had good prognostic significance, because disease recurred
only in patients with high-grade tumours. We also analysed the reproducibility and prognostic
value of the proportion of solid growth (defined as less than 50% vs. 50% or more areas of
squamous and nonsquamous solid growth). In fact, this is a simplification of the FIGO grad-
ing system that leaves out the subdivision of more or less than 5% solid growth, and the
differentiation between squamous and nonsquamous solid growth, and excludes the influence
of nuclear atypia on the final grade. Although some have reported that nuclear grading is a
good prognosticator and has good reproducibility,12 others have questioned its prognostic
value and its reproducibility.6,9,10 Zaino et al,9 in their study of 88 patients with endometrial
carcinoma, found that the prognosis for patients who had architectural grade 2 tumours with
either high or low nuclear grade was similar, bringing into question the need for the inclusion
of nuclear atypia within the FIGO guidelines for grading.
Simply dividing patients into groups with high-grade and low-grade tumours based only on
the proportion of solid growth (50% or less vs. more than 50%) proved to have an interob-
server reproducibility that was better compared with both the binary grading system and the
three-tiered FIGO grading system (80% agreement; κ = 0.50), and it was comparable to the
85% agreement (κ = 0.58) of the artificial, two-tiered FIGO-grading system. Furthermore, its
prognostic value was superior to the two-tiered FIGO grading system and was comparable to
the binary grading system.
In conclusion, although it was shown that the binary grading system proposed by Lax et al 6
had strong prognostic significance for locoregional and distant recurrence and cancer-specific
survival, its reproducibility was poor. The traditional, three-tiered FIGO grading system also
exhibited only fair reproducibility. However, the reproducibility of the combined FIGO
grades 1 and 2 versus grade 3 was much better, but the prognostic value of this artificial, two-
tiered FIGO grading system was less than the value of the binary grading system. Although a
two-tiered grading system has advantages in terms of practical clinical utility, the reproducibil-
ity of the proposed binary system was too low to support its use instead of the traditional,
three-tiered FIGO grading system. Converting the FIGO grading system into an artificial,
two-tiered system improved its reproducibility and affected its prognostic power only moder-
ately; therefore, it is a good alternative. However, a simple architectural grading system
dividing tumours into low-grade and high-grade, based on the proportion of solid growth
(less than 50% vs. 50% or more), was superior to the two-tiered FIGO grading system in
prognostic power and was equally reproducible.
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Chapter 5
Combined E-cadherin, α-catenin and β-catenin expression 
is a favourable prognostic factor
in endometrial carcinoma
Astrid N. Scholten, Riena Aliredjo, Carien L. Creutzberg, Vincent T.H.B.M. Smit
Int J Gynecol Cancer (accepted for publication)
boek04.qxp  23-3-2005  7:56  Pagina 69
70
Abstract
Purpose: Cell adhesion molecules, such as E-cadherin, might be involved in the processes
of tumour invasion and differentiation. The aim of this study was to investigate the expression
of E-cadherin and α- en β-catenin in endometrial carcinoma, and to determine the prognostic
value of these factors.
Materials and Methods: We have investigated the expression of E-cadherin, α- and 
β-catenin by immunohistochemistry in 225 endometrial carcinomas. The correlation between
E-cadherin and the catenins, and their correlation with several histological and clinical param-
eters were analysed.
Results: Decreased E-cadherin, α- and β-catenin expression was observed in 44%, 47%
and 33% of endometrial carcinomas, respectively, and was correlated with histological FIGO
grade 3 (p < 0.001). Decreased E-cadherin expression was more often observed in non-
endometrioid carcinomas (NEEC) than in endometrioid carcinomas (75% versus 43%, 
p = 0.04). Combined preserved E-cadherin, α- and β-catenin expression was an independent
positive prognostic factor for survival in patients with a grade 1-2 carcinoma (p = 0.02).
Conclusions: Decreased E-cadherin expression was found to be associated with histological
grade 3, and with NEEC. Combined preserved E-cadherin, α- and β-catenin expression was a
significant prognostic factor.
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Introduction
Epithelial cadherin (E-cadherin) is a member of the cadherin family of cell adhesion mole-
cules. It is a transmembrane glycoprotein that joins adjacent epithelial cells together via a
calcium-dependent binding mechanism. E-cadherin proteins of adjacent cells interact in the
intercellular space. Binding of the cytoplasmic protein β-catenin to the intracellular part of 
E-cadherin and to α-catenin, which in turn is linked to the cytoskeleton, is necessary for a
properly functioning E-cadherin protein.1 Since E-cadherin is needed to keep neighbouring
cells attached, it has been suggested that impaired function of this cadherin might lead to
invasive potential of malignant epithelial tumours. Recently, it became clear that E-cadherin is
not only a cell-cell adhesion molecule, but it is also somehow involved in the process of cell
differentiation, although so far the underlying mechanism is unclear.2,3 In several malignan-
cies, such as breast and prostate cancer, a correlation has been found between the expression of
E-cadherin and the histological grade.3,4 So far, only a few studies have focused on the signifi-
cance of E-cadherin expression in endometrial carcinoma. Decreased expression was found to
be associated with increasing histological grade and with deep myometrial invasion.5-7
This study was done to investigate, by immunohistochemistry, the expression of E-cadherin
and α- and β-catenin in a large series of 225 patients with endometrial carcinoma, with a fol-
low-up of more than 10 years. We analysed the correlation between E-cadherin, α- catenin
and β-catenin, their association with several histological and clinical characteristics, and the
prognostic significance of these factors.
Material and methods 
Cases
Between January 1984 and December 1993, 253 patients with endometrial cancer were treat-
ed with surgery and radiotherapy at the Leiden University Medical Center. Details of
treatment and outcome have been published previously.8 For most patients (91%) surgery
consisted of a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Peritoneal
fluid was sent for cytological evaluation in 21% of cases. A pelvic staging lymphadenectomy
was performed in 4% of cases; and pelvic and periaortic node sampling was performed in 5%
of cases. Postoperative radiotherapy consisted of pelvic irradiation (median dose 40 Gy) fol-
lowed by vaginal brachytherapy (median dose 15 Gy). In 225 cases (89%) formalin-fixed
paraffin-embedded blocks from the tumour could be obtained for immunohistochemical
analyses. All tumours were revised and graded by one pathologist (V.S.), according to the
International Federation of Gynecology and Obstetrics (FIGO) guidelines.9 Two-hundred-
and-thirteen tumours were endometrioid type adenocarcinoma, and 12 consisted of
71
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non-endometrioid type carcinomas (4 malignant mixed mesodermal tumours and 8 papillary
serous carcinomas). There were 168 stage I, 31 stage II and 26 stage III tumours. Most
tumours were FIGO grade 1 (n = 154), 16 were grade 2 and 55 grade 3. For myometrial inva-
sion not only the depth (less than 50%, n = 85 vs. 50% or more, n = 140) but also the pattern
of invasion was recorded: diffusely infiltrating tumours, with nests of tumour cells infiltrating
the myometrium haphazardly, versus tumours with an expansive growth pattern, with pushing
borders and a continuous line between tumour and unaffected myometrium.10 A pushing bor-
der was found in 83 cases, an infiltrating pattern in 131 cases, and in 11 cases there was no
invasion or the pattern of invasion could not be assessed. All patients have been followed for a
minimum of 6 years (median follow-up 11.6 years, range 6.3 - 16.2 years) or until death.
Immunohistochemistry
Paraffin sections (4 m) were mounted on saline-coated slides. Immunohistochemistry was per-
formed with the MARK 5 Immunostainer (DPC, Breda, The Netherlands). Primary
antibodies used in this study were anti-E-cadherin, clone 36 (1:2000, Transduction
Laboratories), anti-β-catenin, clone 14 (1:1000, Transduction Laboratories) and anti-α-
catenin, clone 5 (1:100, Transduction Laboratories). All the antibodies were monoclonal in
type. Prior to incubation, all sections were subjected to antigen retrieval in a microwave with a
boiling solution of 10mM citrate buffer, pH=6.0, for 10 minutes. In case of both anti-catenin
antibodies 0,05% of a common detergent was added tot the citrate buffer as described previ-
ously.11 Bound primary antibodies were visualised with subsequent incubations with
biotinylated polyvalent IgG and HRP-labelled streptavidin (Ultravision, Labvision, Fremont,
USA), followed by 0.05% diaminobenzidine and 0.0015% hydrogen peroxide. Slides were
briefly counterstained in Mayer's haematoxylin. As negative controls, irrelevant IgG's at the
same protein concentration as the primary antibody were used instead of the primary anti-
body. As positive controls, sections of cervix (E-cadherin), and skin ( α- and β-catenin) were
used.
Scoring
All specimens were evaluated semi-quantitatively and independently by two investigators (A.S.
and R.A.), blinded to patient outcome and tumour characteristics. In case of disagreement, a
third opinion was sought (V.S.) and consensus was achieved together. Slides were scored for
the intensity of the membranous staining of E-cadherin, α- catenin and β-catenin (SI) and for
the proportion of positive tumour cells (PTCs) according to a scoring system that has been
used previously by Moreno-Bueno et al.12 The SI could vary from 0 (absent), 
1 (weak), 2 (moderate) to 3 (strong, as in normal endometrium, Figure 1). The PTCs varied
from 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) to 4 (> 75%). The degree of membranous
staining, the staining score, was calculated as the sum of SI and PTCs (range 0-7).
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Statistical analysis
Correlations between E-cadherin, α- and β-catenin, and other parameters were analysed using
the chi-square test. Survival rates were calculated using the Kaplan-Meier method and differ-
ences between survival curves were assessed with the log-rank test. Multivariate analyses of
prognostic factors were performed using the Cox proportional hazards model. We preferred a
dichotomous scoring system for E-cadherin, α-catenin and β-catenin, since this would be
more useful in daily clinical practice. Therefore we conducted several Cox regression analyses
for E-cadherin, and similarly for α- and β-catenin, each time analysing the factor with a dif-
ferent cut-off point. Based on the change in log likelihood, the dichotomous scoring system
with the strongest prognostic power was determined for each factor. The optimal cut-offs were
found to be between a total score of 4 and 5, thus leading to the definition of preserved
expression of E-cadherin, α-catenin and β-catenin when the total staining score was 5 or
more, and decreased expression when the score was 4 or less. We have combined FIGO grades
1 and 2 in the outcome analyses of the current study, because in previous studies recurrence
and survival rates for patients with grade 1 and grade 2 tumours were found to be comparable,
and the reproducibility of grade 2 was shown to be poor.8,13 All p-values are based on two-
sided tests, with p < 0.05 considered statistically significant.
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Figure 1. E-cadherin expression in endometrial carcinoma. (A) Absent in tumour cells (short arrows), strong in
normal endometrial glands (long arrows). (B) Weak. (C) Moderate. (D) Strong.
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Table 2. Correlations between E-cadherin, and α- and β-catenin and the histological grade
Histological grade
Total 1 2 3
Cell adhesion molecule n (%) n (%) n (%) N (%) p-value
E-cadherin expression
preserved 125 (56) 99 (44) 7 (3) 19 (9)
decreased 100 (44) 55 (24) 9 (4) 36 (16) < 0.001
α-catenin expression
preserved 120 (53) 89 (40) 10 (4) 21 (9)
decreased 105 (47) 65 (29) 6 (3) 34 (15) < 0.001
β-catenin expression
preserved 150 (67) 116 (52) 10 (4) 24 (11)
decreased 75 (33) 38 (17) 6 (2) 31 (14) < 0.001
Table 1. Staining scores of E -cadherin and α-, and β-catenin, and combined scores*
E-cadherin α-catenin β-catenin Combined score* 
n (%) n (%) n (%) n (%)
Staining score
7 14 (6) 6 (2.5) 17 (8)
6 44 (19) 60 (26) 62 (27)
5 67 (30) 54 (24) 71 (32)
preserved expression 125 (56) 120 (53) 150 (67) 69 (31)
4 58 (26) 67 (30) 66 (29)
3 34 (15) 33 (15) 9 (4)
2 6 (3) 4 (2) 0
0 2 (1) 1 (0.5) 0
decreased expression 100 (44) 105 (47) 75 (33) 156 (69)
Total 225 (100) 225 (100) 225 (100) 225 (100)
* Combined score: preserved expression = preserved expression of E-cadherin, α-catenin, AND β-catenin
decreased expression = decreased expression of E-cadherin, α-catenin, OR β-catenin 




Total staining scores of E-cadherin, α-catenin
and β-catenin are shown in Table 1. For all
factors there was a strong correlation
between the staining intensity and the pro-
portion of positive tumour cells (p ≤ 0.003).
Preserved E-cadherin, α- and β-catenin
expression, defined as a staining score of 5 or
more, was found in 125 (56%), 120 (53%)
and 150 (67%) tumours, respectively. There
was a strong correlation between the expres-
sion of E-cadherin, α-catenin and β-catenin.
Among the tumours with decreased E-cadherin expression (staining score of 4 or less), signifi-
cantly more tumours showed decreased α-catenin expression (61% of tumours with decreased
E-cadherin versus 35% of tumours with preserved E-cadherin expression, p < 0.001) and
decreased β-catenin expression (50% versus 20%, p < 0.001). There was also a strong correla-
tion between α- and β-catenin expression (p < 0.001). Combining the E-cadherin, α-catenin
and β-catenin scores resulted into 69 cases (31%) with preserved expression of all three fac-
tors. Among the 156 cases with decreased expression of one or more factors, there were 
68 cases with decreased expression of one factor (44%), 52 cases with decreased expression of
two factors (33%) and 36 cases with decreased expression of all three factors (23%). 
Correlations
A significant inverse correlation between the staining score of E-cadherin, α- and β-catenin
and the histological grade was demonstrated (Table 2). The distribution of histological grades
according to the staining score of E-cadherin (score 0-7) is shown in Figure 2. Expression of
E-cadherin, α-catenin and β-catenin was not correlated to the pattern or the depth of
myometrial invasion or stage. Tumours with an E-cadherin score of 0, 2, 3, 4, 5, 6 and 7,
showed deep myometrial invasion in 100%, 33%, 68%, 62%, 61%, 64% and 57%, respec-
tively, i.e. 62% of tumours with preserved E-cadherin and 63% of tumours with decreased
E-cadherin expression had deep myometrial invasion (p = 0.68). Decreased E-cadherin expres-
sion was significantly more often observed in non-endometrioid type carcinomas (NEECs)
than in endometrioid endometrial carcinomas (EECs): 75% (9/12) and 43% (91/213),
respectively, (p = 0.04).
Figure 2. Distribution of histological grades
according to the staining score of 
E-cadherin.
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Outcome
In univariate analyses, E-cadherin, α-catenin and β-catenin was all found to have prognostic
significance, with decreased expression leading to decreased cancer-specific survival rates
(CSS) (p = 0.008, 0.03 and 0.03, respectively). Five- and 10-year survival rates were 88% and
88% for patients with tumours showing preserved E-cadherin expression, versus 79% and
71% for those with decreased E-cadherin expression. Similar differences in survival rates were
found for the catenin scores. Other significant prognostic factors for CSS were histological
grade (p < 0.001), histological subtype (p < 0.001), stage (p < 0.001) and the pattern of
myometrial invasion (p = 0.01). In multivariate analysis, however, E-cadherin, α- and 
β-catenin lost their statistical significance (p = 0.14, 0.17 and 0.32, respectively), and the sig-
nificant independent prognostic factors for CSS were found to be histological grade and stage.
When combining the scores of E-cadherin, α-catenin and β-catenin, we found that tumours
with preserved expression of all three factors had significantly better CSS rates than tumours
that with decreased expression of one or more factors (5-year CSS 91% and 81%, respectively,
p = 0.02), although in multivariate analysis this statistical significance was lost (p = 0.06). 
No significant differences were found when comparing outcomes for tumours with decreased
expression of one, two or three factors (details not shown). Among the patients with grade 
1-2 tumours (n = 170), those with a tumour that had preserved expression of E-cadherin, 
α-catenin and β-catenin had a significantly better survival than patients with tumours with
decreased expression of one or more of these factors (5-year CSS 97% and 89%, 
respectively, p = 0.02, Figure 3). This remained significant in multivariate analysis 
(p = 0.02, Table 3). The prognosis for patients with a grade 3 tumour (n = 55) was not influ-
Table 3. Univariate (UV) and multivariate (MV) analyses of prognostic factors for endometrial cancer related death, for patients with grade 1-2 tumour
UV               MV     
p-value HR* (95% CI) p-value
FIGO stage II 5.0 (1.9-13.3) 0.001
III < 0.001 5.7 (1.5-21.3) 0.009
Pattern of myometrial invasion infiltrating 0.03 3.1 (1.0-9.4) 0.04
Depth of myometrial invasion ≥ 50% 0.12 1.5 (0.5-4.0) 0.48
E-cadherin, α-catenin and β-catenin decreased expression 0.02 4.3 (1.2-14.8) 0.02
HR: hazard ratio; CI: confidence interval
* Hazard ratios for stage II and III compared with stage I; an infiltrating pattern of invasion compared with pushing borders; deep myometrial 
invasion (≥ 50%) compared with superficial invasion (< 50%); decreased expression of E-cadherin, α- and/or β-catenin compared with preserved
expression of all three factors
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enced by the combined expression of E-cad-
herin, α-catenin and β-catenin. Comparable
results were obtained when analysing only
stage I grade 1-2 tumours. Among these
patients (n = 132), those with a tumour that
showed preserved expression of E-cadherin,
α-catenin and β-catenin had a significantly
better survival than those with tumours that
showed decreased expression of one or more
of these factors (5-year CSS 100% and 93%,
respectively, p = 0.02).
Discussion
In this series of 225 endometrial cancers, decreased E-cadherin expression was found in 100
tumours (44%). There was a strong correlation between expression of E-cadherin and expres-
sion of α- and β-catenin, which might have been expected since both catenins are necessary
for a properly functioning E-cadherin.1 Previously reported percentages of decreased or nega-
tive E-cadherin expression in endometrial carcinoma vary from 11% to 60%.5-7,12 There are
several possible explanations for this wide range of incidences. First, the relatively small size of
most series (30 to 113 cases studied). Second, the use of different scoring systems, and differ-
ent cut-off points. Generally, methods in which the intensity and quantity of E-cadherin
expression are combined, are considered a more relevant evaluation of E-cadherin expression
than intensity or proportion scores alone.14-16 We have therefore scored both the intensity and
the proportion of immunopositivity adding up to a total staining score of 0-7. We have cho-
sen the cut-off values after analyses of the prognostic power of the resulting scoring systems,
and thus tumours with a staining score of 4 or less were defined as having decreased expres-
sion, and tumours with a staining score of 5 or more as having preserved expression of
E-cadherin, α-catenin or β-catenin. In contrast, Holcomb et al 7 considered tumours to be E-
cadherin negative when less than 4% of the tumour cells were positive (in their series 11%
were negative). Leblanc et al 6 reported 27% of endometrial carcinomas to have less than 10%
positive cells. Sakuragi et al 5 divided endometrial cancers in three categories, with positive,
heterogeneous or negative E-cadherin expression, and reported heterogeneous or negative
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Figure 3. Cancer-specific survival in patients with a
grade 1-2 tumour, according to combined 
E-cadherin, α- and β-catenin expression 
(p = 0.02).
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expression in 60% of the tumours. Moreno-Bueno et al 12 scored both the staining intensity
and the percentage of positive tumour cells, however, they defined decreased expression as
having a score of 5 or less, but did not explain why they chose this cut-off point. Decreased
expression of E-cadherin was observed in 60% of tumours. A third reason for the wide range
of reported E-cadherin expression rates is the difference between the studies in the proportion
of endometrioid type (EEC) and non-endometrioid type carcinomas (NEEC). In our study,
including 12 (5%) NEECs, significantly more NEECs showed decreased expression of E-cad-
herin as compared to EECs, 75% versus 43% (p = 0.04). In the study by Moreno-Bueno et al
12 a higher proportion (27%) of all cases were NEECs, which was most likely the major cause
of the higher rate of decreased E-cadherin expression found in their study (60% versus 44% in
ours). In other cancers, e.g. breast and gastric cancer, the association between histological sub-
type and expression of E-cadherin has been demonstrated as well, with decreased expression
occurring more often in lobular than in ductal carcinomas of the breast,17,18 and in diffuse type
gastric cancer.19 Studies on endometrial carcinoma are less conclusive. One study, comparing
E-cadherin expression in 10 papillary serous carcinomas and 14 papillary endometrioid carci-
nomas, found no difference between these histological subtypes.20 Another study, comparing
17 EECs and 17 serous carcinomas, found E-cadherin expression to be more prominent in
serous carcinomas than in EECs,21 whereas a third larger study analysing 113 endometrial car-
cinomas found, similar to our results, that decreased expression of E-cadherin significantly
more often occurred in NEECs than in EECs (87% versus 50%).12 This difference of E-cad-
herin expression between different histological subtypes is in concordance with previous
studies, which showed that different molecular abnormalities were involved in carcinogenesis
of EECs and NEECs.22
Since cell adhesion molecules such as E-cadherin are needed to retain adhesion between
neighbouring cells, it has been suggested that an impaired function of E-cadherin could lead
to invasive potential in malignant epithelial tumours. This was confirmed in an experimental
study that showed in a variety of human cancer cell lines that non-invasive cell lines expressed
E-cadherin protein, whereas invasive carcinoma cell lines had lost E-cadherin expression.3 In
vivo, however, reduced E-cadherin expression has been demonstrated in lobular carcinoma in
situ of the breast23 and in atypical endometrial hyperplasia.12 This indicates that decreased
expression of E-cadherin is not purely a predictor of invasiveness, but can also occur in non-
invasive lesions. We did not find a correlation between decreased expression of E-cadherin and
deeper myometrial invasion or a more infiltrating pattern of invasion. Some studies on
endometrial carcinoma did5 and some did not7 show a correlation between decreased expres-
sion of E-cadherin and deeper myometrial invasion. It seems that a complex biological process
such as stromal invasion is not regulated by a single molecular alteration, but caused by a
sequence of changes, including alterations in several cell adhesion molecules.
Cadherins not only function as cell-cell adhesion molecules, but are also somehow involved in
the process of differentiation, although so far the underlying mechanism is unclear.2,3 In
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endometrial carcinoma a correlation between the expression of E-cadherin and the histological
grade has been shown.5-7 We confirmed this strong correlation between decreased E-cadherin,
α- or β-catenin expression and histological grade (p < 0.001). Preserved expression of E-cad-
herin was significantly more often observed in grade 1 tumours, predominantly consisting of
glands, than in grade 3 tumours, with areas of solid fields. Thus decreased expression of E-
cadherin is associated with a diffuse growth pattern, lacking tubular or gland formation, just
as in lobular breast cancer17,18 and diffuse type gastric cancer.19 This supports the theory that E-
cadherin may somehow be involved in the process of gland formation.
E-cadherin expression has been shown to be an independent prognostic factor in breast can-
cer.16 So far, in endometrial cancer no independent prognostic power of E-cadherin has been
reported. We demonstrated that patients with a tumour that showed combined preserved 
E-cadherin, α-catenin and β-catenin expression had a better prognosis than patients with
decreased expression of one of these factors. No significant difference was found when com-
paring outcome for tumours with decreased expression of respectively one, two or three
factors. This underlines the fact that these three factors are closely related, and that a defect in
one of these factors may already cause a disturbance in their function. Since E-cadherin, α-
catenin and β-catenin expression was correlated to histological grade, which is known to be a
strong independent prognosticator,8,13 we further analysed their prognostic significance in
grade 1-2 tumours as opposed to grade 3 tumours. It was found that within the group of
patients with a grade 1-2 tumour (n = 170), combined preserved E-cadherin, α-catenin and
β-catenin expression was an independent prognostic factor for survival (5-year CSS 97% ver-
sus 89%, hazard ratio: 4.3, p = 0.02).
In the treatment of patients with stage I endometrial carcinoma, the indication for postopera-
tive radiotherapy is tailored to the prognostic factors histological grade 3, deep myometrial
invasion and advanced age.13 Within the subset of patients with a stage I, grade 1-2 tumour,
we found that none of the patients with preserved expression of E-cadherin, α-catenin and β-
catenin recurred within the observed period (minimum follow-up 6 years). This might imply
that analysis of the expression pattern of these factors could be used to identify patients with
such a favourable prognosis that adjuvant treatment could be omitted. Larger, prospective
studies of E-cadherin and catenin expression would be needed to confirm this.
In conclusion, this study shows in a large group of endometrial carcinomas, with a long fol-
low-up, that decreased E-cadherin expression is associated with histological grade 3, and is
more often seen in NEECs than in EECs. Furthermore, combined E-cadherin, α- and 
β-catenin expression was shown to be an independent prognostic factor for survival. Within
the group of patients with a grade 1-2 tumour, preserved expression of all three factors identi-
fied a subset of patients with favourable outcome.
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Chapter 6
Nuclear β-catenin is a molecular feature of type I 
endometrial carcinoma
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Abstract
Purpose: Two types of endometrial carcinoma can be distinguished: type I tumours, which
are oestrogen-related and are typically low-grade endometrioid carcinomas; and type II
tumours, which are unrelated to oestrogen stimulation and are often non-endometrioid carci-
nomas. The molecular abnormalities involved in carcinogenesis appear to be different for
these tumour types. The aim of this study was to test the hypothesis that an abnormality in
the Wnt/β-catenin signalling pathway is a molecular feature of type I endometrial carcinoma.
Materials and methods: This study investigated nuclear β-catenin by immunohistochem-
istry in 233 endometrial carcinomas and analysed its correlations with several
immunohistochemical, histological, and clinical parameters, such as proliferation rate (Ki-67),
expression of oestrogen and progesterone receptors, and survival.
Results: Nuclear β-catenin expression was observed in 39 cases (16%). All tumours
expressing nuclear β-catenin were endometrioid adenocarcinomas, were significantly better
differentiated, and were more often hormone receptor-positive than tumours without nuclear
β-catenin. No correlation with proliferation rate was found. 
Conclusions: It was found that several features of type I endometrial carcinoma occur sig-
nificantly more often in tumours expressing nuclear β-catenin, suggesting that an abnormality
in the Wnt/β-catenin signalling pathway, resulting in nuclear β-catenin immunopositivity, is a
molecular feature of a subset of type I endometrial carcinomas.
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Introduction
β-catenin was originally identified as a component of the cadherin-mediated intercellular adhe-
sion system.1 Subsequent studies have demonstrated that it also functions as a downstream
transcriptional factor in the Wnt signalling pathway, functioning as an oncogene.2 In normal
epithelial cells, in the absence of a Wnt signal, a cytoplasmic complex comprising β-catenin,
adenomatous polyposis coli (APC), axin, and GSK-3β mediates the phosphorylation of 
β-catenin and, as a consequence, the targeted degradation of this protein via the ubiquitin-pro-
teasome pathway.3,4 Mutations of genes affecting this complex (e.g. β-catenin in endometrial
carcinoma5-7 or, in the case of colon cancer, mutation of APC8) severely impair the down-regula-
tion of β-catenin, which leads to an excess of cytoplasmic protein. This results in concomitant
translocation of β-catenin into the nucleus, where it can form transcriptionally active complexes
with T-cell factor/lymphoid enhancer factor (Tcf/Lef ), resulting in the activation of several
genes, including c-myc and cyclin D19,10 (Figure 1). In colon carcinoma cells, this has been
shown to result in uncontrolled cellular proliferation and polyp formation.8,11,12
Only a few studies have focused on the significance of nuclear β-catenin in endometrial can-
cer.5,6,13 In 1983, Bokhman was the first to describe two different types of endometrial
carcinoma.14 Type I tumours are oestrogen-related, often preceded by a pre-cancerous condition
(hyperplasia), and are typically low-grade endometrioid carcinomas of the endometrium (EECs).
They usually develop in pre- and peri-menopausal women and in general have a good prognosis.
On the other hand, type II tumours are unrelated to oestrogen stimulation, mostly developing in
atrophic endometrium, presumably preceded by endometrial intraepithelial carcinoma (EIC),
and are often papillary serous and clear cell carcinomas, i.e. non-endometrioid endometrial car-
cinomas (NEECs). They affect older women and usually have a poor clinical outcome.15
The molecular abnormalities involved in the development of endometrial carcinomas appear to
be different for both types of tumour. In type II carcinomas, p53 mutations have been reported
in both the invasive and the intraepithelial components in up to 90% of cases.16,17 No molecular
abnormality has been found to be responsible for the majority of tumours of the endometrioid
phenotype. The type I tumour category seems to encompass a more heterogeneous group of
tumours, with different molecular alterations, such as PTEN mutations and microsatellite insta-
bility, being reported to occur during tumorigenesis.18 In this study, we have analysed correlations
of nuclear β-catenin with several immunohistochemical, histological, and clinical parameters,
such as the proliferation rate, the expression of the oestrogen (ER) and progesterone (PR) recep-
tors, and survival, in a large series of 233 endometrial tumour samples. The aim of the study was
to test the hypothesis that abnormalities in the Wnt/β-catenin signalling pathway occur only in
type I endometrial carcinoma. The following questions were addressed: Are tumours expressing
nuclear β-catenin endometrioid carcinomas? Are they mostly well-differentiated tumours, with
less myometrial invasion? Do they present at a lower stage? Are these tumours more often hor-
mone receptor-positive, affecting predominantly pre-menopausal women? And, finally, is the
prognosis for patients with a tumour expressing nuclear β-catenin better?
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Materials and methods
Tissue samples
Between January 1984 and December 1993, 253 patients with endometrial cancer were treat-
ed with surgery and radiotherapy at the Leiden University Medical Center. Patient and
tumour characteristics have been published previously.19 In 233 cases (92%), formalin-fixed,
paraffin-embedded blocks from the tumour could be obtained for immunohistochemical
analyses.
Immunohistochemistry
Paraffin sections (4µm) were mounted on saline-coated slides. Immunohistochemistry was
performed with the MARK 5 Immunostainer (DPC, Breda, The Netherlands). The primary
antibodies used in this study were anti-β-catenin, clone 14 (1:1000; Transduction
Laboratories), anti-Ki-67, clone MIB-1 (1:200; DAKO, Glostrup, Denmark), anti-oestrogen
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Figure 1. Wnt/β-catenin pathway. (A) In the 
absence of a Wnt signal, β-catenin is
degraded through interaction with a 
complex comprising APC, GSK-3β
and axin.
(B) Mutations of β-catenin suppress the degrada-
tion of β-catenin, leading to the accumulation of
β-catenin in the cytoplasm and nucleus and activa-
tion of Tcf/Lef target genes, such as c-myc and
cyclin D1.
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receptor, clone 1D5, (1:100; DAKO) and anti-progesterone receptor (1:100; DAKO). All the
antibodies were monoclonal in type except the progesterone receptor antibody, which was a
rabbit polyclonal. Prior to incubation, all sections were subjected to antigen retrieval in a
microwave with a boiling solution of 10 mM citrate buffer, pH 6.0, for 10 minutes. Bound
primary antibodies were visualized with subsequent incubations with biotinylated polyvalent
IgG and HRP-labelled streptavidin (Ultravision, Labvision, Fremont, USA), followed by
0.05% diaminobenzidine and 0.0015% hydrogen peroxide. Slides were briefly counterstained
in Mayer's haematoxylin. As negative controls, irrelevant IgGs at the same protein concentra-
tion as the primary antibody were used instead of the primary antibody. As positive controls,
sections of skin (β-catenin), tonsil (Ki-67), and breast carcinoma (ER and PR) were used.
Scoring
Specimens were scored by one observer (A.S.), who was blinded to the patients' outcome and
other histological and non-histological covariates. β-catenin slides were scored for the presence
or absence of a nuclear staining pattern. In accordance with a previous study,7 nuclear staining
was considered positive when at least 1% of the cells showed nuclear immunopositivity.
Furthermore, the degree of membranous β-catenin staining was determined. Both the intensi-
ty of the membranous staining (staining intensity, SI) and the proportion of positive tumour
cells (positive tumour cells, PTCs) were scored; the SI could vary from 0 (none), 1 (weak), 2
(moderate) to 3 (strong) and the PTCs varied from 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-
75%) to 4 (> 75%). The degree of membranous staining (staining score) was calculated as the
sum of SI and PTC (range 0, 2-7). On the ER and PR slides, the tumour was judged to be
positive when at least one area showed clear positive nuclear staining. The proliferation rate
was evaluated quantitatively, by counting the number of nuclei positive for Ki-67 per 200
cells, in five different high-power fields (200x).
Statistical analysis
Survival rates were calculated using the Kaplan-Meier method, and differences between sur-
vival curves were assessed with the log-rank test.19 Correlations between nuclear β-catenin and
other parameters were analysed using the chi-square test. Ki-67 was analysed semi-quantita-
tively, dividing the scores into quartiles. All p-values are based on two-sided tests, with 
p < 0.05 considered statistically significant.
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Results
Nuclear β-catenin expression was observed
in 39 of the 233 cases (16%). In many of
these cases, the nuclear staining was most
prominent in areas of squamous metaplasia
(Figure 2). All 233 tumours showed some
degree of membranous staining, reflecting
the function of β-catenin in the cadherin-
mediated intercellular adhesion system. 
We analysed whether a correlation existed
between nuclear β-catenin expression and
the degree of membranous staining, as deter-
mined by the combination of the staining
intensity and the proportion of positive
tumour cells. Decreased membranous staining, defined as a staining score of 4 or less, was
found in 33% of tumours with nuclear β-catenin and in 48% of tumours without nuclear 
β-catenin staining. This difference was not statistically significant (p = 0.09). The presence of
nuclear β-catenin staining did not correlate with the rate of proliferation, as determined by
the percentage of positive Ki-67 cells (X2 = 5.666, p = 0.34). Several differences were observed
between the tumours with and those without nuclear β-catenin staining (Table 1). 
All 39 tumours with nuclear β-catenin were endometrioid adenocarcinomas (EECs). In the
group without nuclear β-catenin, 6% (n = 12) consisted of non-endometrioid type carcino-
mas (NEECs) [4 malignant mixed Müllerian tumours (MMMTs) and 8 papillary serous
carcinomas]. This difference in histological subtypes between the two groups was not statisti-
cally significant. Considering the very small number of NEECs (n = 12), these were excluded
from further analyses, which were focused on the comparison of the EECs with and without
nuclear β-catenin. There was a significant difference in histological grade between EECs with
and without nuclear β-catenin. In the group of tumours expressing nuclear β-catenin, 90%
were grade 1 and 8% grade 3, in contrast to 68% grade 1 and 23% grade 3 in the group with-
out nuclear β-catenin (p = 0.02). Patients with tumours showing nuclear β-catenin-expression
were significantly more often pre-menopausal (15% vs. 4%, p = 0.01) and had somewhat
higher survival rates, although this difference was not statistically significant (5- and 10-year
cancer-specific survival rates of 92% and 87%, vs. 85% and 82%, respectively, p = 0.78).
The number of tumours with a positive hormone receptor was significantly higher in the
EECs with nuclear β-catenin: 82% were ER-positive and 77% PR-positive, compared with
56% (p = 0.003) and 46% (p = 0.001) in the group without nuclear β-catenin. No significant
correlation was found between nuclear β-catenin staining and tumour stage, or between
nuclear β-catenin and the depth of myometrial invasion. 
Figure 2. Nuclear β-catenin staining in a 
well-differentiated endometrioid-type
adenocarcinoma with abundant squa-
mous metaplasia.
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The hormone receptors were statistically significant prognostic factors for survival. Patients
with an ER-positive EEC (129/212 tumours, 61%) had a 5-year cancer-specific survival rate
of 89%, as opposed to 80% for those with ER-negative tumours (p = 0.003). Women with a
PR-positive positive tumour (111/214 tumours, 52%) had a 5-year cancer-specific survival
rate of 91%, versus 80% for those with PR-negative tumours (p = 0.02). There was a strong
correlation between both hormone receptors: 43% of all cases were positive for both receptors,
30% were negative for both receptors, and only 27% were positive for just one of the hor-
mone receptors (p < 0.001). Patients who had a tumour with a high proliferation rate had a
lower cancer-specific survival rate than those with less proliferating tumours, but the differ-
Table 1. Correlations between the pattern of β-catenin staining and several histological and non-histological parameters
β-catenin
nuclear staining  n (%) no nuclear staining  n (%) p-value
Tumour grade
1 35 (90) 123 (68)
2 1 (2) 17 (9)
3 3 (8) 42 (23) 0.02
FIGO stage
I 28 (72) 140 (77)
II 8 (20) 22 (12)
III 3 (8) 20 (11) 0.35
Myometrial invasion
< 50% 12 (31) 72 (40)
≥ 50% 27 (69) 110 (60) 0.31
Menopausal state
pre-menopausal 6 (15) 8 (4)
post-menopausal 33 (85) 174 (96) 0.01
Estrogen Receptor
positive 32 (82) 97 (56)
negative 7 (18) 76 (44) 0.003
Progesterone Receptor
positive 30 (77) 81 (46)
negative 9 (23) 94 (54) 0.001
Cancer-specific survival
5-year (%) 92 85
10-year (%) 87 82 0.78
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ence in survival rate was not statistically significant. When dividing tumours into groups with
0-25%, 26-50%, 51-75% and 76-100% cells positive for Ki-67, the 5-year cancer-specific
survival rates were 87%, 87%, 75% and 75%, respectively (p = 0.61).
Discussion
In this series of 233 endometrial carcinomas, nuclear β-catenin expression was found in 39 of
233 tumours (16%), which is in accordance with the percentages reported in other studies,
varying from 13 to 44%.5-7,18,20-23 In the positive cases, nuclear β-catenin staining was most
prominent in squamous metaplastic areas, an observation that has previously been reported by
Saegusa and Okayasu.23 The biological meaning of this phenomenon remains to be clarified,
especially since there were also well-differentiated tumours with abundant squamous meta-
plastic areas that did not show nuclear β-catenin staining. In normal epithelial cells,
abnormalities in the Wnt/β-catenin signalling pathway, leading to a nuclear β-catenin staining
pattern, result in the activation of several genes, including c-myc and cyclin D1.9,10 In colon
carcinoma cells, this has been shown to cause uncontrolled cellular proliferation.8 In normal
endometrium, nuclear β-catenin has been observed during the mid- and late proliferative
phase of the menstrual cycle, which supports the idea that the nuclear localization of 
β-catenin indicates a condition in which cell proliferation signals are activated in the
endometrium.20 We therefore analysed whether tumours with nuclear β-catenin showed a
higher proliferation rate than tumours without nuclear β-catenin. However, we did not find
such a correlation. This is probably due to the fact that in all malignant tumours, by defini-
tion, there is an imbalance between the rate of proliferation and the amount of cell loss.
Apparently, in this study, the type of genetic abnormality causing this imbalance (an abnor-
mality in the Wnt/β-catenin signalling pathway or some other abnormality) did not result in a
significantly different proliferation rate. β-catenin mutations and the subsequent nuclear accu-
mulation of β-catenin protein have only been found in the endometrioid type of endometrial
carcinomas.18,22 We therefore hypothesized that abnormalities in the Wnt/β-catenin signalling
pathway occur only in type I endometrial carcinoma. The aim of this study was to test this
hypothesis in a large series of endometrial carcinomas, by analysing different features of type I
carcinoma in tumours with and tumours without nuclear β-catenin. We found that all
tumours with nuclear β-catenin were endometrioid adenocarcinomas (EECs). The same
observation was made by Palacios et al,18 who analysed the presence of nuclear β-catenin in 40
endometrial carcinomas. Thirteen expressed nuclear β-catenin and, similar to our observation,
all were EECs, in contrast to tumours without nuclear β-catenin, of which nine (33%) were
non-endometrioid type carcinomas (NEECs). The difference in histological subtype that we
observed in our study, i.e. 0% (0/39) NEECs in tumours with nuclear β-catenin, versus 6%
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(12/194) NEECs in tumours without nuclear β-catenin, was not statistically significant. 
This is probably due to the small number of NEECs (n = 12) in our study. Considering the
very small number of NEECs, these were excluded from further analyses, which were focused
on comparison of the EECs with and without nuclear β-catenin. We found that EECs with
nuclear β-catenin were significantly better differentiated than tumours without nuclear 
β-catenin: 90% of the tumours with nuclear β-catenin were well differentiated. Experimental
studies have shown that the Wnt/β-catenin signalling pathway is involved in several processes
concerning morphological differentiation. It has an important role during embryogenesis and
stem cell differentiation,8,24 and tcf-1 (a downstream factor in the Wnt/β-catenin signalling
pathway) has been found to be essential for T-cell differentiation.25 This might explain why
tumours with nuclear β-catenin are predominantly well differentiated. We found patients who
had EECs with nuclear β-catenin to be significantly more often pre-menopausal than those
without nuclear β-catenin. Furthermore, tumours with nuclear β-catenin were significantly
more often PR- and ER-positive than tumours without nuclear β-catenin. Nei et al 20 have
looked at β-catenin in normal endometrium, endometrial hyperplasia, and endometrial cancer
samples. They found no correlation between the intensity of ER and PR staining and the
nuclear staining of β-catenin in hyperplasia and cancer. However, in normal endometrium,
they found a tendency for the samples in the proliferative phase, with strong staining for ER,
to show nuclear staining for β-catenin. Furthermore, oestrogens have been reported to stimu-
late resting cells (G0 phase) to enter the cell cycle, a process that is preceded by increased
expression of c-myc and cyclin D1,26 two of the genes that are also activated in the Wnt/β-
catenin signalling pathway. This suggests that the Wnt/β-catenin signalling pathway can be
stimulated by serum oestrogen, but it might also just be that both pathways converge towards
a common step that includes up-regulation of cyclin D1 and c-myc to promote proliferation.21 
Although tumours with nuclear β-catenin were more often well differentiated and hormone
receptor-positive, we did not find a significant difference in prognosis. The cancer-specific
survival rates were better for patients with tumours expressing nuclear β-catenin than for
those with tumours without nuclear β-catenin (92% vs. 85% at 5 years, respectively), but this
difference was not statistically significant. This may be related to the relatively small number
of tumours expressing nuclear β-catenin (39/221). 
In conclusion, we found several features of type I endometrial carcinoma to occur significant-
ly more often in EECs with nuclear β-catenin than in EECs without nuclear expression:
well-differentiated tumours, expression of hormone receptors and pre-menopausal status.
These results strongly suggest that abnormalities in the Wnt/β-catenin signalling pathway,
resulting in a nuclear β-catenin staining pattern, are molecular features of a subset of type I
endometrial carcinomas. Although the number of NEECs (type II) in this series is relatively
small, the absence of nuclear β-catenin staining in these cases at least suggests that this molec-
ular event is less important in the development of these carcinomas. We are currently
investigating whether nuclear β-catenin develops together with or apart from other molecular
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abnormalities in type I carcinomas. More research into this area might enable us to divide the
large, heterogeneous group of type I endometrial carcinomas into several subgroups, each with
its specific molecular abnormalities and clinical aspects.
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Summary and general discussion
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Summary and general discussion
Endometrial cancer is the most common malignancy of the female genital tract in Western
countries, affecting around 1500 new patients per year in the Netherlands. After breast, col-
orectal, and lung cancer, endometrial cancer is the fourth most common invasive tumour in
Dutch women. It accounts for about 5% of all tumours. The prognosis of endometrial cancer
patients depends on several clinical and pathological factors, such as age, International
Federation of Gynaecology and Obstetrics (FIGO) stage, depth of myometrial invasion, histo-
logical subtype, lymph vascular space invasion and histological grade. In general, patients with
endometrial carcinoma have a good prognosis, since most patients (75-80%) present with
early-stage disease (FIGO stage I). Five-year survival rates for FIGO stage I endometrial can-
cer are 80-90%. In the Netherlands, about 300 women per year die of the disease, mainly of
distant metastases. Standard treatment consists of a total abdominal hysterectomy with bilat-
eral salpingo-oophorectomy. The indication for postoperative pelvic radiotherapy is tailored to
prognostic factors. The purpose of this thesis was to evaluate the significance of these prognos-
tic factors in endometrial carcinoma and to investigate the incidence and significance of
molecular abnormalities and their potential role as prognostic factors for clinical practice.
In this thesis the patient data and histology specimens of two patient cohorts have been
analysed. First, the data and specimens of a retrospective study from the Leiden University
Medical Center (LUMC) were analysed. Secondly, data and histology specimens from the
multicentre Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) trial
were analysed. In chapter 2 long-term outcome of the patients from the LUMC study is
reported. This study included 253 patients with endometrial carcinoma stages I to III. The
histological slides were reviewed and the prognostic value of stage, age, histological grade, his-
tological subtype, depth of myometrial invasion (less than 50% vs. 50% or more) and pattern
of invasion (infiltrating pattern vs. pushing borders) was analysed. Median follow-up was 11.7
years. Overall and cancer-specific (CSS) actuarial survival rates at 5 years were 77% and 85%,
and 10-year survival rates were 64% and 82%, respectively. The 5-year rates of locoregional
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recurrences and distant metastases were 7% and 15%. These results are in accordance with
rates reported in previous studies.1-4 In multivariate analysis, stage (hazard ratios [HRs]: 3.4 for
stage II, 3.7 for stage III), histological grade (HR: 3.6 for grade 3), age (HR: 2.4 for age 60
years or over), and pattern of myometrial invasion (HR: 2.2 for infiltrating pattern) had inde-
pendent prognostic significance for CSS. In 1988 Mittal and Barwick5 were the first to
describe the prognostic significance of the pattern of myometrial invasion. They reported that
patients with a diffusely infiltrating pattern of growth were at increased risk of death from
endometrial carcinoma. Five-year mortality of the five patients with a diffusely infiltrating
pattern was 40%, compared with 13.3% mortality at five years for a control group of 15
patients with carcinomas without this diffusely infiltrating pattern. However, this difference
was not statistically significant,6 most likely due to the small numbers in this study. The results
of three subsequent studies on the prognostic value of the pattern of myometrial invasion are
not uniform.7-9 Two studies did find the pattern of myometrial invasion to have prognostic
power,7,9 one study did not find a difference in recurrence or survival rates according to the
pattern of myometrial invasion.8 In other malignancies, such as cervical cancer10 and several
head and neck malignancies,11,12 the pattern of invasion of the surrounding stromal tissue has
been found to be a significant prognostic factor for survival. The number of studies that have
focussed on the prognostic significance of the pattern of invasion in endometrial cancer is
small, as well as the number of patients in these studies (n = 93-112). Furthermore, the defini-
tion of an infiltrating pattern of invasion differs between the studies. In our study, the pattern
of invasion was defined as infiltrative if glands or tumour cells haphazardly infiltrated the
myometrium, by which there was no longer a more or less smooth border between tumour
and myometrium, even when this happened in only a small part of the tumour. This pattern
was found to be a strong independent prognosticator for a decreased CSS. The depth of inva-
sion, on the other hand, had only borderline prognostic significance in univariate analysis (p =
0.07), and lost its statistical significance in multivariate analysis. In theory, deep invasion into
the outer part (outer 50% to 33%) of the myometrial width increases the risk of vessel inva-
sion, since the major afferent lymph and blood vessels of the myometrium are located in the
subserosal areas. However, when a tumour invades the myometrium for more than 50% with
an expansive growth pattern, it pushes the myometrium away rather than infiltrating it, with-
out reaching the vessels in the outer part of the myometrium, and thus without an increased
risk of regional or distant spread. That might explain the observed superior prognostic power
of the pattern of myometrial invasion as compared to the depth of invasion. Furthermore,
determination of the depth of myometrial invasion can be difficult, and depends on the way
the macroscopic specimen has been processed, which may be subject to sampling errors.
Determination of the pattern of myometrial invasion is less dependent on the way the macro-
scopic specimen has been processed, and might therefore be more reproducible. Since it has
strong prognostic power, the pattern of myometrial invasion is a good alternative for the
depth of myometrial invasion as prognostic factor for clinical practice. At pathology review, a
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shift from grade 2 to grade 1 was seen in 112 of the 144 grade 2 tumours (78%). There are
several features of the FIGO grading system that may be responsible for this considerable shift
of the tumour grade at revision. The FIGO grading system is based on the extent of nonsqua-
mous solid growth and on nuclear atypia.13 Grade 1 tumours have 5% or less areas of solid
growth, grade 2 6% to 50%, and grade 3 more than 50% solid growth. In case of marked
nuclear atypia, a grade 1 or 2 is raised by one grade. Distinguishing between squamous and
nonsquamous solid growth can be difficult. Furthermore, determining whether the percentage
of nonsquamous solid growth is more or less than 5% is somewhat arbitrary. And the determi-
nation of the degree of nuclear atypia is highly subjective, as illustrated by the 35% agreement
(κ = 0.22) for nuclear grading reported by Lax et al.14 Furthermore, at time of review, slides
were consistently scored according to the FIGO 1988 grading criteria, whereas these criteria
had not yet been implemented in all hospitals at the time of the patients' treatment (between
1984 and 1993). No difference in CSS between grade 1 and grade 2 was found (94% vs. 90%
5-year CSS for original grade and 92% vs. 94% for grade after review), whereas grade 3 was
found to be a significant adverse prognostic factor (p < 0.001). A similar shift from grade 2 to
grade 1 was observed at pathology review of the PORTEC trial. The PORTEC trial included
715 patients with a stage IC, grade 1 or 2, or stage IB, grade 2 or 3 endometrial carcinoma, of
which 714 could be evaluated. The slides of 569 patients (80%) could be obtained for pathol-
ogy review. Originally, 21%, 68% and 11% of tumours were assigned grade 1, 2 and 3,
respectively, while after pathology review, this changed to 69%, 16% and 15%. Eligibility for
the trial was based on the grade assigned by the regional pathologist. After surgery, patients
were randomised to receive pelvic radiotherapy (RT) or no further treatment. In 2000 the first
results of this trial were published. The analysis described in chapter 3, with a median follow-
up for patients alive of 97 months, was conducted to evaluate long-term outcome and to
analyse prognostic factors after central pathology review. The 10-year locoregional relapse
rates were 5% and 14% in the RT group and in the control group, respectively (p < 0.001).
There was no significant survival difference between the treatment arms, with 10-year overall
survival rates of 66% in the RT group and 73% in the control group (p = 0.09). In multivari-
ate analyses, postoperative radiotherapy was found to be an independent prognostic factor for
locoregional control (HR: 3.9; p < 0.001). Due to the shift in tumour grade that was observed
at pathology review, 134 tumours were diagnosed as grade 1 tumours with superficial myome-
trial invasion (stage IB), and would not have met the inclusion criteria for the study. After
exclusion of these 134 cases from the analyses, the outcome of the trial remained essentially
the same, with 10-year recurrence rates of 5% for the RT group and 17% for the control
group (p < 0.001), and 10-year overall survival rates of 65% and 70%, respectively (p = 0.23).
This analysis, with long-term follow-up and central pathology review, confirmed the previous
PORTEC trial results, that postoperative pelvic radiotherapy for stage I endometrial carcino-
ma significantly decreases the risk of locoregional recurrence, but does not provide a survival
advantage.
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In view of the poor reproducibility and limited value of the intermediate grade, as described
in chapter 2 and chapter 3, a two-tiered grading system seems preferable. In 2000 Lax et al 14
proposed a binary grading system that discriminates between high-grade and low-grade
tumours based on the proportion of solid growth (50% or less vs. more than 50%), the pat-
tern of myometrial invasion (infiltrating vs. pushing border), and the presence of tumour cell
necrosis. A review of 800 patients with endometrioid adenocarcinoma was conducted (chap-
ter 4), in order to compare the interobserver variability, and the clinical utility of the two- and
three-tiered grading systems. The prognostic significance and the interobserver variability, of
the three-tiered FIGO grading system and the binary grading system, as published by Lax et
al,14 were analysed and compared. All slides were reviewed and graded independently by two
pathologists. The interobserver agreement for both systems was moderate, with 70% and 73%
agreement rates for the FIGO (κ = 0.41) and binary (κ = 0.39) grading systems, respectively.
When converting the FIGO grading system into an artificial, two-tiered grading system
(grade 3 vs. grades 1-2), the agreement was much better (agreement rate, 85%; κ = 0.58). Of
the 3 criteria for the binary grading system, amount of solid growth (less than 50% vs. 50%
or more) had the greatest reproducibility (agreement rate, 80%; κ = 0.50). Both the two-
tiered FIGO and the binary grading systems were significant predictors of locoregional
recurrence, distant recurrence, and cancer-specific survival (hazard ratios [HRs]: 1.7, 2.5, and
2.6, for FIGO and 2.1, 4.1, and 3.8, for the binary grading system). The amount of solid
growth was a strong prognostic factor for these three endpoints as well (HRs: 2.4, 3.9, and
3.8, respectively). This simple architectural two-tiered grading system based on the proportion
of solid growth (less than 50% vs. 50% or more) had superior prognostic power and greater
reproducibility than both the FIGO and the binary grading systems.
Determining the histological tumour grade is an essential part of pathological diagnosis, as the
histological grade has prognostic and therapeutic implications. In general, a grading system
has to be practical, reproducible and clinically relevant, having clear prognostic power. For a
diversity of gynaecological and non-gynaecological malignancies, such as colorectal adeno-
mas,15 the value of the intermediate grade or the intermediate degree of dysplasia is a matter of
debate, and a trend is observed to change traditionally used three-tiered grading systems into
two-tiered grading systems. In 1988, in the United States of America, the classification of
squamous intraepithelial cervical neoplasia (CIN) was changed from CIN I, CIN II, and CIN
III to low-grade squamous intraepithelial lesion (SIL) and high-grade SIL, because of an
observed lack of reproducibility.16 For malignant ovarian germ cell tumours a higher degree of
interobserver agreement for a two-tiered grading scale as compared to a three-tiered grading
scale was observed (κ = 0.66 and κ = 0.54, respectively), leading to the recommendation of
the use of a two-tiered grading system for this malignancy.17 Furthermore, an analysis of the
impact of pathological review in more than 500 gynaecological cancers revealed a change in
diagnosis in 33% of cases (including a change in the histological grade in the majority of
cases), which would have altered patient management in 12%.18 Comparable observations
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were made in our study. After pathology review, 34 irradiated patients (13.4%) were diag-
nosed as having a stage I, grade 1 tumours with less than 50% myometrial invasion, implying
that there was no need for postoperative radiotherapy in these patients. Similarly in the
PORTEC trial, 134 tumours (24%) were diagnosed at pathology review as grade 1 with
superficial myometrial invasion, for which radiotherapy would not have been indicated.
Approximately one half of these patients where randomised to receive postoperative radiother-
apy. There are disadvantages attached to changing the grading system that is used worldwide.
It would be difficult to compare outcome of new therapies or new treatment strategies with
historical control groups when criteria for prognostic variables have been changed. Still, the
use of this simple binary grading system that divided tumours into low-grade lesions and
high-grade lesions based on the proportion of solid growth (less than 50% vs. 50% or more)
might eventually lead to better patient care, considering its superior reproducibility without
loss of prognostic power compared with the FIGO grading system.
Two types of endometrial carcinoma can be distinguished. Type I tumours are oestrogen-relat-
ed and are typically low-grade endometrioid carcinomas, with positive oestrogen- (ER) and
progesterone receptors (PR). They usually develop in an oestrogen rich environment (pre- and
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Figure 1. Dualistic model of endometrial carcinogenesis. (A) Type I pathway. (B) Type II pathway. 
(EEC: endometrioid endometrial carcinoma, NEEC: non- endometrioid endometrial carcinoma, 
MI: microsatellite instability).
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peri-menopausal state), and in general have a good prognosis. Type II tumours are unrelated
to oestrogen stimulation and are often non-endometrioid carcinomas. The molecular abnor-
malities involved in carcinogenesis appear to be different for these tumour types. In chapter 5
and chapter 6 the potential role of cell adhesion molecule E-cadherin, and α- and β-catenin
as prognostic factors for clinical practice has been investigated. Furthermore, their significance
in the carcinogenesis of either of the two types of endometrial carcinoma was evaluated. 
The expression of E-cadherin, α- and β-catenin was investigated by immunohistochemistry in
225 endometrial carcinomas (chapter 5). E-cadherin is a member of the cadherin family of
cell adhesion molecules. α- and β-catenin are necessary for a properly functioning 
E-cadherin protein. Since E-cadherin is needed to keep neighbouring cells attached, it has
been suggested that impaired function of this cadherin might lead to invasive potential of
malignant epithelial tumours. Furthermore, E-cadherin is also somehow involved in the
process of cell differentiation, although so far the underlying mechanism is unclear. The inten-
sity of the membranous staining (score 0-3) and the proportion of positive tumour cells (score
0-4) were scored, adding up to a total score of 0-7. Normal endometrial glands show strong
membranous staining. Decreased expression was defined as a score of 4 or less. A score of 5 or
more was defined as preserved expression. Decreased E-cadherin, α- and β-catenin expression
was observed in 44%, 47% and 33% of endometrial carcinomas, respectively. It was found
that decreased expression of E-cadherin, α- or β-catenin was correlated with histological grade
3 (p < 0.001), implying that it is associated with a diffuse growth pattern, lacking tubular or
gland formation, just as in lobular breast cancer and diffuse type gastric cancer. This supports
the theory that E-cadherin may somehow be involved in the process of gland formation.
Decreased E-cadherin expression was more often observed in non-endometrioid carcinomas
than in endometrioid carcinomas (75% versus 43%, p = 0.04). This might imply that
decreased expression of E-cadherin, possibly caused by an E-cadherin mutation,19 is a molecu-
lar abnormality that is more often involved in the carcinogenesis of type II than in the
carcinogenesis of type I endometrial carcinoma. Expression of E-cadherin, α-catenin and 
β-catenin was not correlated to the depth, or to the pattern of myometrial invasion. It seems
that a complex biological process such as stromal invasion is not regulated by a single molecu-
lar alteration, but is caused by a sequence of changes, including alterations in several cell
adhesion molecules. Assessment of E-cadherin, α- and β-catenin had prognostic value in a sub-
set of patients. Among patients with grade 1 or grade 2 tumours, those with preserved
expression of E-cadherin, α- and β-catenin had a significantly better 5-year CSS of 97% com-
pared with 89% 5-year CSS for those with decreased expression of one or more of these factors
(p = 0.02).
β-catenin is not only a component of the cadherin-mediated intercellular adhesion system, it
also functions as an oncogene in the Wnt signalling pathway. In normal epithelial cells a cyto-
plasmic complex comprising β-catenin mediates the phosphorylation of β-catenin and, as a
consequence, the targeted degradation of this protein. A mutation in the β-catenin gene
101
boek04.qxp  23-3-2005  7:57  Pagina 101
severely impairs the down-regulation of its protein, which leads to an excess of cytoplasmic 
β-catenin. This results in concomitant translocation of β-catenin into the nucleus, where it
can form transcriptionally active complexes with T-cell factor/lymphoid enhancer factor
(Tcf/Lef ), resulting in the activation of several genes, including c-myc and cyclin D1, which
can cause uncontrolled cellular proliferation. Since β-catenin mutations and the subsequent
nuclear accumulation of β-catenin protein have only been found in the endometrioid type
endometrial carcinomas, it was hypothesized in chapter 6 that abnormalities in the 
Wnt/β-catenin signalling pathway occur only in type I endometrial carcinoma. Of all 233
endometrial carcinomas investigated, nuclear β-catenin expression was observed in 39 cases
(16%). All tumours expressing nuclear β-catenin were endometrioid adenocarcinomas
(EECs). EECs expressing nuclear β-catenin were more often well differentiated than EECs
without nuclear β-catenin, and were more often ER-positive and PR-positive. Furthermore,
patients with tumours showing nuclear β-catenin-expression were significantly more often
pre-menopausal and had higher survival rates. These results suggest that an abnormality in the
Wnt/β-catenin signalling pathway, leading to a nuclear β-catenin staining pattern, is a molec-
ular feature of a subset of type I endometrial carcinomas.
Other molecular abnormalities found in type I endometrial carcinoma are PTEN mutations
(found in 35-50% of type I carcinomas), microsatellite instability (20-30%), K-ras mutations
(15-30%), p53 mutations (10-20%) and HER-2/neu overexpression (10-15%). So far, no
molecular abnormality has been found to be responsible for the majority of tumours of the
endometrioid phenotype. K-ras mutations and β-catenin mutations have been found in sim-
ple hyperplasic lesions. Microsatellite instability, however, has only been observed in atypical
hyperplasic lesions adjacent to endometrial carcinoma and may therefore be a late event in the
transition from atypical hyperplasia to carcinoma. Since p53 mutations are mostly found in
grade 3 EEC, and never in endometrial hyperplasia, p53 mutations in EEC seem to be late
events, related to dedifferentiation of these tumours. In NEEC, on the other hand, p53 muta-
tions are reported in up to 90% of the cases, both in the invasive and in the pre-malignant
intraepithelial components, suggesting this to be an early event in carcinogenesis of type II
endometrial carcinoma (Figure 1).
Better understanding of the carcinogenesis of the two different types of endometrial carcino-
ma might lead to improved means of treatment of endometrial cancer, and may provide the
foundation for molecularly directed therapies. Results of the first microarray studies support
the concept of the two types of endometrial carcinoma.20,21 In these studies, the global gene
expression patterns of EEC and NEEC were compared. The differences in gene expression
between these histological subtypes might provide a basis for further investigations into the
carcinogenesis of the two types of endometrial carcinoma. Such comprehensive genomic
analyses are probably the only way to fully understand tumour biology and will give the best
information about the carcinogenesis of endometrial cancer. However, fresh tumour material
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is required for these analyses, and in daily practice, most macroscopic specimens of endome-
trial cancer are put in formalin immediately after the operation. Recently, in the Netherlands a
prospective microarray study was started to analyse the differences in gene expression patterns
between endometrial carcinomas of patients previously treated for breast cancer with tamox-
ifen, and endometrial carcinomas of patients previously treated for breast cancer without
tamoxifen. Despite numerous studies on molecular abnormalities in endometrial carcinoma,
this has not yet resulted in implementation of molecular features as prognostic factors in clin-
ical practice. Their prognostic power, if present at all, has not been found to be superior to
other, traditional factors. More research into this area, especially studies analysing patterns of
gene expression, rather than focussing on a limited number of genes, will hopefully result in
identification of significant molecular prognostic factors that will benefit patient care.
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Samenvatting
In Nederland krijgen per jaar ongeveer 1500 vrouwen baarmoederkanker. Doorgaans ontstaat
dit in de binnenste slijmvlieslaag van de baarmoeder, het endometrium. Dit wordt een
endometriumcarcinoom genoemd. De prognose van patiënten met een endometriumcarci-
noom is in het algemeen gunstig, en hangt samen met een aantal factoren. 
- De leeftijd van de patiënt, waarbij oudere patiënten een slechtere prognose hebben dan
jongere. 
- Het stadium van de ziekte op het moment van behandeling, d.w.z. de mate waarin de ziek-
te is doorgegroeid in het omringende weefsel en in hoeverre deze is uitgezaaid naar de
lymfeklieren of andere organen. Bij het merendeel van de patiënten (75-80%) is de kanker
beperkt tot de baarmoeder (stadium I). 
- De mate van ingroei in de omringende spierlaag (myometrium invasie diepte). Diepe
ingroei in deze omringende spierlaag verhoogt de kans op invasie van de bloed- en lymfe-
vaten die gelegen zijn in het buitenste deel van het myometrium, waardoor de tumorcellen
versleept kunnen worden naar de lymfeklieren in het bekken of elders in het lichaam
(bijvoorbeeld de longen). 
- Het type kankercel (histologisch subtype).
- De differentiatiegraad van het endometriumcarcinoom, dit is de mate van uitrijping van de
kankercellen, ofwel in hoeverre zij nog lijken op gewone endometriumcellen. Dit zegt iets
over delingssnelheid en de mate van agressiviteit van de tumor. Het endometriumcarci-
noom wordt gegradeerd volgens het International Federation of Gynecology and Obstetrics
(FIGO) graderingsysteem, en wordt onderverdeeld in drie graden: goed gedifferentieerde
(graad 1), matig gedifferentieerde (graad 2) en slecht gedifferentieerde tumoren (graad 3).
Omdat het endometriumcarcinoom meestal snel klachten geeft in de vorm van vaginaal
bloedverlies, wordt het vaak vroeg ontdekt en zijn de overlevingskansen over het algemeen
goed. Vijf jaar na het stellen van de diagnose is 80-90% van de patiënten met een stadium I
endometriumcarcinoom nog in leven. Uiteindelijk overlijden in Nederland per jaar ongeveer
300 vrouwen aan endometriumcarcinoom.
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De standaardbehandeling van het endometriumcarcinoom bestaat uit chirurgische verwijder-
ing van de baarmoeder, de eileiders en de eierstokken. Afhankelijk van de leeftijd van de
patiënt, de differentiatiegraad van de tumor en de myometrium invasie diepte, worden patiën-
ten na de operatie (postoperatief ) bestraald op het operatiegebied en de lymfklierstations in
het bekken. Bij elke vorm van kanker is er sprake van een ongecontroleerde aanmaak van
cellen. Dit wordt veroorzaakt door een verstoring (mutatie) in één of meer van de genen (het
erfelijk materiaal van de cel), die verantwoordelijk zijn voor de controle op de aanmaak of
afbraak van cellen. Door middel van moleculair biologisch onderzoek kunnen deze gen-
afwijkingen of de gevolgen hiervan (veranderde expressie van eiwitten) worden aangetoond.
Het doel van dit proefschrift is het belang van verschillende prognostische factoren voor het
endometriumcarcinoom te onderzoeken. Daarnaast is onderzoek gedaan naar het vóórkomen
van moleculaire afwijkingen bij het endometriumcarcinoom en naar hun mogelijke prognos-
tische betekenis voor de dagelijkse klinische praktijk.
In dit proefschrift worden de patiëntgegevens en het pathologisch materiaal van twee cohorten
geanalyseerd. Allereerst wordt een cohort geanalyseerd van 253 patiënten die tussen 1984 en
1993 in het Leids Universitair Medisch Centrum (LUMC) zijn bestraald vanwege een
endometriumcarcinoom. Ten tweede wordt de pathologische beoordeling beschreven van de
Postoperatieve Radiotherapie bij Endometriumcarcinoom (PORTEC) studie, die tussen 1990
en 1997 in de meeste centra in Nederland is uitgevoerd om de waarde van postoperatieve
radiotherapie bij patiënten met een stadium I endometriumcarcinoom te bepalen. Na operatie
werd er geloot of de patiënt bestraald zou worden of geen verdere therapie zou ontvangen. In
deze studie zijn 715 patiënten geïncludeerd met een stadium I, graad 1 of 2 endometriumcar-
cinoom dat diep in het myometrium infiltreerde (50% of meer), of een stadium I, graad 3
tumor met oppervlakkige myometrium invasie (minder dan 50%). Er konden 714 patiënten
geëvalueerd worden. Het proefschrift is als volgt opgebouwd. Hoofdstuk 1 bevat een
algemene inleiding. In hoofdstuk 2 en hoofdstuk 3 worden de lange termijn resultaten van
de patiënten uit respectievelijk de LUMC studie en de PORTEC studie beschreven. In hoofd-
stuk 4 wordt de waarde van verschillende graderingsystemen voor het endometriumcarcinoom
vergeleken. En in hoofdstuk 5 staat de prognostische betekenis van E-cadherine, α-catenine
en β-catenine centraal, waarna hoofdstuk 6 beschrijft wat de rol van β-catenine is bij het
ontstaan van het endometriumcarcinoom. 
Hoofdstuk 2 beschrijft de lange termijn overleving van de 253 patiënten uit de LUMC
studie. Retrospectief is geanalyseerd wat het prognostisch belang was van het tumorstadium,
de leeftijd van patiënte, de differentiatiegraad, het histologisch subtype, de diepte van de
myometrium invasie (meer of minder dan de helft) en het patroon van de invasie (een infiltr-
erende tumor versus een tumor die het myometrium meer wegdrukt dan infiltreert, een
zogenaamde "pushing border"). De mediane follow-up bedroeg 11.7 jaar.
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Na vijf en tien jaar waren nog respectievelijk  77% en 64% van de patiënten in leven. De
kanker-specifieke overleving (cancer-specific survival, CSS), d.w.z. het percentage patiënten
dat nog in leven is of is overleden aan andere oorzaken dan het endometriumcarcinoom, was
na vijf en tien jaar respectievelijk 85% en 82%. Na vijf jaar was bij 7% van de patiënten een
loco-regionaal recidief ontstaan (hernieuwde tumorgroei op de voormalige plaats van de baar-
moeder of in de omringende lymfeklieren), en bij 15% waren uitzaaiingen elders in het
lichaam ontstaan. Sterke, onafhankelijk prognostische factoren voor de CSS bleken te zijn:
- het tumorstadium (een 3.5 maal hoger risico om te overlijden aan de ziekte bij een verder
gevorderd stadium van de ziekte t.o.v. stadium I),
- de differentiatiegraad (3.6 maal hoger overlijdensrisico bij een slecht gedifferentieerde
tumor t.o.v. een goed gedifferentieerde tumor) en 
- het patroon van myometrium invasie (2.2 maal hoger overlijdensrisico bij een infiltrerend
invasie patroon t.o.v. een patroon met "pushing borders").
De diepte van de myometrium invasie bleek in onze studie geen onafhankelijk prognostische
factor te zijn. Diepe ingroei in het myometrium verhoogt de kans op invasie van de vaten die
gelegen zijn in het buitenste deel daarvan. Echter, in het geval van een tumor met een "push-
ing border" die het myometrium voor meer dan de helft lijkt in te groeien, duwt de tumor de
omringende spierlaag meer weg dan dat deze het myometrium daadwerkelijk ingroeit, waar-
door de vaten in het buitenste deel van het myometrium niet bereikt worden. Daarnaast blijkt
het in de praktijk lastig te zijn om de precieze diepte van de myometrium invasie te bepalen,
en hangt deze beoordeling af van de manier waarop de baarmoeder na de operatie verwerkt is.
Aangezien het patroon van myometrium invasie beter reproduceerbaar lijkt en een sterkere
prognostische factor is, is dit een goed alternatief voor de myometrium invasie diepte als prog-
nostische parameter in de dagelijkse praktijk.
Voor deze LUMC studie zijn alle pathologie coupes van de tumoren opnieuw beoordeeld en
gegradeerd. Hierbij bleken 112 van de 144 (78%) tumoren die oorspronkelijk als matig gedif-
ferentieerd waren gegradeerd, nu als goed gedifferentieerd beoordeeld te worden. Deze grote
verschuiving had geen effect op de CSS voor de groep goed gedifferentieerde en de groep
matig gedifferentieerde tumoren (94% versus 90% 5-jaars overleving volgens de originele
graad, en 92% versus 94% volgens de gereviseerde graad), terwijl een slecht gedifferentieerde
tumor een duidelijk slechtere prognose bleek te hebben (5-jaars overleving 63%). Een soort-
gelijke verschuiving van graad 2 naar graad 1 werd gevonden tijdens de pathologische revisie
van de PORTEC studie. Van 569 (80%) patiënten uit deze studie konden de coupes verkre-
gen worden voor pathologische revisie. Oorspronkelijk waren 21%, 68% en 11% van alle
tumoren respectievelijk graad 1, 2 en 3. Na revisie waren dit respectievelijk 69%, 16% en
15%. In 2000 zijn de eerste resultaten van de PORTEC studie gepubliceerd. In hoofdstuk 3
wordt de analyse beschreven met een mediane follow-up van 97 maanden, die verricht is
teneinde de lange termijn resultaten te bekijken en de prognostische factoren opnieuw te eval-
ueren, maar nu met de gereviseerde differentiatiegraad. Oorspronkelijk waren de tumoren
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door regionale pathologen gegradeerd.
Na tien jaar werden 5% en 14% loco-regionale recidieven gevonden in respectievelijk de
radiotherapie (RT) groep en de controle groep (p < 0.001). Postoperatieve radiotherapie bleek
een sterke, onafhankelijke prognostische factor voor het optreden van een loco-regionaal reci-
dief (3.9 maal hoger risico op een loco-regionaal recidief in de controle groep vergeleken met
de RT groep). Er was geen significant verschil in overleving tussen de beide behandelgroepen,
met 10-jaars overlevingspercentages van respectievelijk 66% (RT) en 73% (controle, 
p = 0.09). Ten gevolge van de verschuiving van graad 2 naar graad 1 die tijdens de pathologis-
che revisie gevonden werd, werden 134 tumoren gediagnosticeerd als graad 1 met
oppervlakkige myometrium invasie. Dit betekent dat deze eigenlijk niet voor inclusie in de
studie in aanmerking zouden zijn gekomen. Wanneer deze 134 patiënten uit de analyses geëx-
cludeerd werden, veranderden de uitkomsten nauwelijks, met 10-jaars loco-regionale
recidiefpercentages van 5% in de RT groep en 17% in de controle groep (p < 0.001) en 
10-jaars overlevingspercentages van 65% en 70% (p = 0.23).
Deze analyse met lange follow-up en met gereviseerde pathologie, bevestigt de eerdere uitkom-
sten van de PORTEC studie dat postoperatieve radiotherapie voor stadium I endometrium-
carcinomen de kans op een loco-regionaal recidief significant vermindert, maar zonder over-
levingswinst. Vanwege deze verbetering van de loco-regionale controle, blijft postoperatieve
radiotherapie geïndiceerd voor patiënten met een stadium I endometriumcarcinoom met een
verhoogd risico op een loco-regionaal recidief. Momenteel is er voor patiënten met een stadi-
um I endometriumcarcinoom een indicatie voor postoperatieve radiotherapie, indien
tenminste twee van drie negatief prognostische factoren aanwezig zijn (graad 3, meer dan 50%
myometrium invasie, en leeftijd ouder dan 60).
Gezien de slechte reproduceerbaarheid en beperkte klinische waarde van graad 2, zoals
beschreven in hoofdstuk 2 en 3, lijkt een tweedelig graderingsysteem zinvoller dan het huidige
driedelige graderingsysteem, aangezien dit beter correleert met de prognose van de patiënt en
waarschijnlijk beter reproduceerbaar is. Daarom werd een graderingstudie opgezet met tumor-
weefsel van 800 patiënten uit de beide studies (hoofdstuk 4). Verschillende graderingsystemen
zijn met elkaar vergeleken: enerzijds het traditioneel gebruikte driedelige FIGO graderingsys-
teem (goed, matig, slecht gedifferentieerd, resp. graad 1, 2 en 3), en anderzijds een nieuw
tweedelig (binair) graderingsysteem (laag- en hooggradig) dat gebaseerd is op de hoeveelheid
solide tumorgroei (in tegenstelling tot groei in buizen, zoals dat ook gezien wordt in normaal
endometrium), het patroon van de myometrium invasie (infiltrerend versus "pushing bor-
ders") en de aanwezigheid van necrose (afgestorven tumorcellen). Alle coupes zijn,
onafhankelijk van elkaar, door twee pathologen gegradeerd. Als maat voor de reproduceer-
baarheid werd gekeken naar het percentage waarin overeenstemming was tussen beide
pathologen. De overeenstemming tussen de beide pathologen voor de twee systemen was
matig, gezien de 70% overeenstemming voor het FIGO graderingsysteem en 73% voor het
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binaire systeem. Wanneer het FIGO systeem omgezet werd in een kunstmatig tweedelig 
systeem (graad 1 en 2 versus graad 3), was de overeenstemming veel beter (85% overeenstem-
ming). Wanneer gekeken werd naar de drie afzonderlijke criteria van het binaire systeem,
bleek de beoordeling van de hoeveelheid solide groei (meer of minder dan 50%) het best
reproduceerbaar (80% overeenstemming). Zowel het kunstmatige FIGO graderingsysteem
(graad 1 en 2 vs. graad 3) als het binaire graderingsysteem waren sterke prognostische factoren
voor de kanker-specifieke overleving. Patiënten met een FIGO graad 3 tumor hadden een 2.6
maal hoger risico om te overlijden aan de tumor dan patiënten met een graad 1 tumor.
Hooggradige tumoren volgens het binaire systeem gaven een 3.8 maal hoger overlijdensrisico
t.o.v. laaggradige tumoren. Ook de hoeveelheid solide groei bleek een sterke prognostische fac-
tor. Tumoren met meer dan 50% solide groei gaven een 3.8 maal hoger overlijdensrisico t.o.v.
tumoren met minder dan 50% solide groei. Dit eenvoudige tweedelige graderingsysteem,
waarin tumoren worden verdeeld in laaggradige en hooggradige lesies op basis van de hoeveel-
heid solide groei (meer of minder dan 50%), had een betere prognostische waarde en
reproduceerbaarheid dan zowel het FIGO als het binaire graderingsysteem. Er zijn nadelen
verbonden aan het veranderen van het graderingsysteem dat wereldwijd gebruikt wordt. Zo zal
het moeilijker zijn om het resultaat van nieuwe behandelmethoden te vergelijken met his-
torische controle groepen als de criteria voor prognostische factoren veranderd zijn. Toch zou
het gebruik van dit simpele tweedelige graderingsysteem, gebaseerd op de hoeveelheid solide
groei, uiteindelijk kunnen leiden tot betere patiëntenzorg, gezien de hogere reproduceer-
baarheid en gelijke prognostische waarde van dit graderingsysteem, vergeleken met het FIGO
graderingsysteem.
Er worden twee typen endometriumcarcinomen onderscheiden.
- Type I tumoren zijn gerelateerd aan het vrouwelijk geslachtshormoon oestrogeen. Het zijn
meestal goed gedifferentieerde endometrioid type carcinomen, met aanwezigheid van hor-
moonreceptoren (positieve expressie). Ze ontstaan vaak vanuit een goedaardige
celproliferatie van het baarmoederslijmvlies (hyperplasie), bij vrouwen die nog niet of kort
in de overgang zijn (pre- of peri-menopausaal) en hebben over het algemeen een goede
prognose.
- Type II tumoren zijn vaak niet-endometrioid type carcinomen die frequenter bij oudere
vrouwen voorkomen en over het algemeen een slechtere prognose hebben.
De moleculaire afwijkingen die betrokken zijn bij het ontstaan van het endometriumcarci-
noom lijken voor beide types verschillend te zijn. In hoofdstuk 5 en 6 is de rol van
E-cadherine, α-catenine en β-catenine bij het ontstaan van beide typen endometriumcarci-
nomen onderzocht, evenals hun mogelijke prognostische betekenis. E-cadherine is een
zogenaamd cel-adhesie molecuul. Het heeft α- en β-catenine nodig om goed te kunnen func-
tioneren. Aangezien E-cadherine zorgt voor de samenhang tussen cellen, is in de literatuur
gesuggereerd dat een verstoorde functie van E-cadherine zou kunnen leiden tot de doorgroei
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van kwaadaardige tumoren naar het omringende weefsel. Verder blijkt E-cadherine ook
betrokken te zijn bij het proces van celdifferentiatie, alhoewel het onderliggende mechanisme
daarvan tot op heden nog onduidelijk is. In hoofdstuk 5 wordt verslag gedaan van een onder-
zoek  waarbij 225 endometriumcarcinomen middels een immunohistiochemische techniek
zijn onderzocht op de expressie van E-cadherine en α- en β-catenine. Verminderde expressie
voor E-cadherine, α-catenine en β-catenine werd gevonden in 44%, 47% en 33% van de
tumoren. Er werd geen verband gevonden tussen de expressie van E-cadherine en de diepte of
het patroon van myometrium invasie. Wel werd een sterke correlatie gevonden tussen een ver-
minderde expressie van E-cadherine, α-catenine en β-catenine, en differentiatiegraad 3 van de
tumor (p < 0.001). Verminderde expressie van E-cadherine werd vaker gevonden bij niet-
endometrioide type dan bij endometrioide type carcinomen (p = 0.04), hetgeen er wellicht op
duidt dat verminderde expressie van dit eiwit (mogelijk het gevolg van een E-cadherine
mutatie) een kenmerk is van type II endometriumcarcinomen. De expressie van E-cadherine
en α- en β-catenine was van prognostisch belang voor een deel van de patiënten met een
endometriumcarcinoom. Van alle patiënten met een goed of matig gedifferentieerde tumor,
hadden diegenen met een normale expressie van zowel E-cadherine als α- en β-catenine een
significant betere 5-jaars kanker-specifieke overleving van 97% vergeleken met de 89% 5-jaars
overleving van patiënten met een tumor die verminderde expressie toonde voor een of
meerdere van deze factoren.
β-catenine is niet alleen een onderdeel van het celadhesie complex waar ook E-cadherine
onderdeel van uitmaakt, maar het functioneert ook als onderdeel van de zogenaamde Wnt-sig-
nalling pathway. Deze pathway bestaat uit een serie processen binnen een cel, uiteindelijk
leidend tot de aanmaak van genen die betrokken zijn bij de proliferatie van de cel. Een ver-
storing binnen deze pathway kan leiden tot een verhoogde aanmaak van deze genen, en dus
tot een ongecontroleerde proliferatie van cellen (een tumor). Een van die verstoringen is een
mutatie van het β-catenine gen. Hierdoor kan het β-catenine eiwit minder goed afgebroken
worden, waardoor een overschot ontstaat, dat naar de kern van de cel verplaatst wordt. 
Het β-catenine eiwit kan zichtbaar gemaakt worden d.m.v. immunohistochemie.
Membraneuze aankleuring van β-catenine is een uiting van de functie van dit eiwit binnen het
celadhesie systeem. Nucleaire (kern) aankleuring van β-catenine is een gevolg van een verstor-
ing binnen de Wnt-signalling pathway zoals hierboven beschreven. Tot op heden is nucleaire
aankleuring van β-catenine alleen aangetroffen bij endometrioid type endometriumcarci-
nomen. Daarom ontstond de hypothese in hoofdstuk 6 dat abnormaliteiten in de
Wnt-signalling pathway alleen voorkomen bij type I endometriumcarcinomen. In deze serie
werden 233 endometriumcarcinomen immunohistochemisch onderzocht op de aanwezigheid
van β-catenine in de kern. Dit werd gezien bij 39 van de 233 tumoren (16%). 
Alleen endometrioid type carcinomen vertoonden nucleaire aankleuring. Tumoren met nucle-
aire β-catenine expressie waren in vergelijking met tumoren zonder deze vorm van aankleuring
significant vaker goed gedifferentieerd (p = 0.02), hadden vaker positieve expressie van hor-
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moonreceptoren (p ≤ 0.003), patiënten waren significant vaker pre-menopausaal (p = 0.01) en
zij hadden een betere kanker-specifieke overleving. Dit alles suggereert derhalve sterk dat een
afwijking in de Wnt-signalling pathway inderdaad een moleculair kenmerk is van type I
endometriumcarcinomen.
Meer kennis omtrent het ontstaan (de carcinogenese) van de twee typen endometriumcarci-
nomen zou kunnen leiden tot nieuwe, verbeterde behandelmethoden voor het
endometriumcarcinoom. De beste manier om de carcinogenese zo volledig mogelijk te door-
gronden, is via veelomvattende genanalyses. Voor zulke analyses is echter vers materiaal nodig,
en in praktijk worden de meeste baarmoederpreparaten direct na de operatie in formaline
gedaan. Tot op heden zijn moleculaire kenmerken van het endometriumcarcinoom nog niet in
gebruik als prognostische factor. Dit komt voornamelijk omdat hun prognostische waarde,
voor zover deze al gevonden werd, niet beter was dan die van andere, traditionele prognostis-
che factoren. Meer onderzoek op dit gebied, met name studies die patronen van genexpressie
onderzoeken, in plaats van zich te richten op een beperkt aantal genen, zal hopelijk resulteren
in de identificatie van significante moleculaire prognostische factoren waar de patiënt baat bij
heeft.
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